[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 35809
1. Walz J, Chun FK, Klein EA, Reuther A, Saad F, Graefen M, Huland H, Karakiewicz PI: Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol; 2009 Feb;181(2):601-7; discussion 607-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
  • PURPOSE: We developed a nomogram predicting the probability of early biochemical recurrence after radical prostatectomy because early recurrence predisposes to distant metastasis and prostate cancer related mortality.
  • MATERIALS AND METHODS: From January 1992 to December 2005, 2,911 patients underwent radical prostatectomy for localized prostate cancer.
  • Age, prostate specific antigen, pathological Gleason sum, surgical margin, extracapsular extension, seminal vesicle invasion and lymph node invasion were considered.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Nomograms. Prostatectomy / methods. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Nov;56(5):885-6 [20965035.001]
  • (PMID = 19084864.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Bolla M, Artignan X, Fourneret P, Brochon D, Ringeisen F, Descotes JL: [Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer]. Bull Cancer; 2006 Nov;93(11):1101-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer].
  • [Transliterated title] L'association hormonothérapie néoadjuvante et irradiation externe dans les cancers de la prostate.
  • Localized carcinoma with intermediate prognostic factors (cT2b, Gleason 7, or baseline PSA ranging between 10 and 20 ng/mL) may be submitted to a 4-month complete androgene blockade with 2 months before irradiation, unless to include patients in ongoing randomized trials.
  • Very high risk prostate cancers, T3-4 N0 M0 or pelvic lymph node involvement (c or pN1) whatever the UICC T stage, need a long term androgen suppression of 3 years or more.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Neoadjuvant Therapy / methods. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / radiotherapy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145579.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 23
  •  go-up   go-down


3. Elabbady AA, Khedr MM: Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml. Int Urol Nephrol; 2006;38(3-4):553-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml.
  • PURPOSE: We evaluate the use of free/total prostate specific antigen (PSA) ratio in improving the prediction of cancers of higher Gleason scores.
  • Out of the 164 patients who underwent TRUS-biopsy, cancer was detected in 62 (37.8%) patients.
  • The mean age for the 62 patients with histologically proven prostate cancer was 62.3+/-5.5 years (49-73).
  • In the 20 patients with free PSA ratio>20%, 1 patient (5%), had prostate cancer of high Gleason score and the remaining 19 (95%) patients had low Gleason scores.
  • CONCLUSIONS: In this study, men with prostate cancer and lower F/T PSA ratio were at a higher risk of having higher Gleason scores (7-10) and those with higher F/T PSA ratio were more likely to have lower Gleason scores.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology


Advertisement
4. Grainger EM, Schwartz SJ, Wang S, Unlu NZ, Boileau TW, Ferketich AK, Monk JP, Gong MC, Bahnson RR, DeGroff VL, Clinton SK: A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen. Nutr Cancer; 2008;60(2):145-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen.
  • Tomato and soy products are hypothesized to reduce the risk of prostate cancer or enhance efficacy of therapy.
  • A study was completed to determine if men with active prostate cancer will adhere to a dietary intervention rich in tomato products and a soy protein supplement men (n = 41) with recurrent, asymptomatic prostate cancer were randomized among 2 groups: Group A (n = 20) consumed tomato products (no soy) for Weeks 0 through 4, targeting a minimum of 25 mg of lycopene/day.
  • No grade II through IV toxicities were observed.
  • Serum prostate-specific antigen decreased between Weeks 0 and 8 for 14 / 41 men (34%).
  • In conclusion, prostate cancer patients will consume diets rich in tomato products and soy with excellent compliance and bioavailability of phytochemicals.
  • Further studies combining tomato and soy foods to determine efficacy for prostate cancer prevention or management are encouraged.
  • [MeSH-major] Carotenoids / therapeutic use. Neoplasm Recurrence, Local / prevention & control. Prostate-Specific Antigen / blood. Prostate-Specific Antigen / drug effects. Prostatic Neoplasms / blood. Prostatic Neoplasms / drug therapy. Soybean Proteins / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444145.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / R01 CA112632
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Soybean Proteins; 36-88-4 / Carotenoids; EC 3.4.21.77 / Prostate-Specific Antigen; SB0N2N0WV6 / lycopene
  •  go-up   go-down


5. Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ, Youngren JF: A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int; 2008 Feb;101(4):436-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
  • OBJECTIVE: To assess the tolerability of the effects of nordihydroguareacetic acid (NDGA) and its effect on prostate-specific antigen (PSA) kinetics in patients with relapsed prostate cancer, as among the many biological effects of NDGA is the inhibition of the insulin-like growth factor 1 receptor (IGF-1R) tyrosine kinase.
  • PATIENTS AND METHODS: Eligible patients were those with an increasing PSA level after definitive local therapy, in either the non-castrate (androgen-dependent prostate cancer, ADPC) or the castrate state (castration-resistant prostate cancer, CRPC) with no evidence of metastatic disease by bone scan or computed tomography of the abdomen or pelvis.
  • There were asymptomatic increases in transaminase in six patients, two of which were grade 3, all occurring at >or=3 months.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Masoprocol / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Prostate-Specific Antigen / drug effects. Prostatic Neoplasms / drug therapy


6. Odedina FT, Kumar N: Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer; 2009 Feb 10;4 Suppl 1:S2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa.
  • BACKGROUND: African American men have the highest prostate cancer morbidity and mortality rates than any other racial or ethnic group in the US.
  • Although the overall incidence of and mortality from prostate cancer has been declining in White men since 1991, the decline in African American men lags behind White men.
  • Of particular concern is the growing literature on the disproportionate burden of prostate cancer among other Black men of West African ancestry in the Caribbean Islands, United Kingdom and West Africa.
  • This higher incidence of prostate cancer observed in populations of African descent may be attributed to the fact that these populations share ancestral genetic factors.
  • To better understand the burden of prostate cancer among men of West African Ancestry, we conducted a review of the literature on prostate cancer incidence, prevalence, and mortality in the countries connected by the Transatlantic Slave Trade.
  • RESULTS: Several published studies indicate high prostate cancer burden in Nigeria and Ghana.
  • Prostate cancer morbidity and/or mortality data from the Caribbean Islands and the United Kingdom also provided comparable or worse prostate cancer burden to that of US Blacks.
  • CONCLUSION: The growing literature on the disproportionate burden of prostate cancer among other Black men of West African ancestry follows the path of the Transatlantic Slave Trade.
  • To better understand and address the global prostate cancer disparities seen in Black men of West African ancestry, future studies should explore the genetic and environmental risk factors for prostate cancer among this group.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1998 Jun;159(6):1984-6; discussion 1986-7 [9598503.001]
  • [Cites] J Natl Med Assoc. 1998 Nov;90(11 Suppl):S720-3 [9828589.001]
  • [Cites] Int J Urol. 2003 Jun;10(6):315-22 [12757603.001]
  • [Cites] Int Braz J Urol. 2003 Jul-Aug;29(4):300-5 [15745552.001]
  • [Cites] BJU Int. 2000 Jun;85(9):1074-7 [10848698.001]
  • [Cites] West Indian Med J. 2001 Jun;50(2):123-9 [11677908.001]
  • [Cites] BJU Int. 2006 Dec;98(6):1216-20 [17125479.001]
  • [Cites] West Indian Med J. 2002 Jun;51(2):64-7 [12232943.001]
  • [Cites] Int Braz J Urol. 2003 Jul-Aug;29(4):306-11; discussion 312 [15745553.001]
  • [Cites] J Natl Med Assoc. 2002 Jul;94(7):619-27 [12126288.001]
  • [Cites] Lancet. 2003 Mar 8;361(9360):859-64 [12642065.001]
  • [Cites] J Natl Med Assoc. 1999 Mar;91(3):159-64 [10203918.001]
  • [Cites] Urology. 2003 May;61(5):987-92 [12736021.001]
  • [Cites] CA Cancer J Clin. 1989 Jan-Feb;39(1):3-20 [2492874.001]
  • [Cites] J Urol. 1997 Apr;157(4):1340-3 [9120935.001]
  • [Cites] East Afr Med J. 1995 May;72(5):283-7 [7555882.001]
  • [Cites] BMC Public Health. 2006;6:159 [16787544.001]
  • [Cites] West Afr J Med. 2004 Apr-Jun;23(2):131-4 [15287291.001]
  • [Cites] Niger Postgrad Med J. 2003 Mar;10(1):1-5 [12717456.001]
  • [Cites] Urology. 2004 Apr;63(4):737-41 [15072891.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1991 Nov-Dec;1(1):21-7 [1845164.001]
  • [Cites] West Afr J Med. 1996 Jan-Mar;15(1):56-60 [8652442.001]
  • [Cites] J Natl Med Assoc. 2006 Apr;98(4):539-43 [16623066.001]
  • [Cites] West Indian Med J. 1995 Sep;44(3):102-5 [8560879.001]
  • [Cites] Prostate. 1980;1(2):185-205 [15619919.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):726-9 [12163325.001]
  • [Cites] Eur Urol. 2008 Jan;53(1):99-105 [17368710.001]
  • [Cites] Ethn Dis. 2002 Fall;12(4):S3-30-3 [12477151.001]
  • [Cites] Int Urol Nephrol. 1981;13(2):159-66 [7327891.001]
  • (PMID = 19208207.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / G12 RR003020
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2638461
  •  go-up   go-down


7. Kilbridge KL, Fraser G, Krahn M, Nelson EM, Conaway M, Bashore R, Wolf A, Barry MJ, Gong DA, Nease RF Jr, Connors AF: Lack of comprehension of common prostate cancer terms in an underserved population. J Clin Oncol; 2009 Apr 20;27(12):2015-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of comprehension of common prostate cancer terms in an underserved population.
  • PURPOSE: To assess the comprehension of common medical terms used in prostate cancer in patient education materials to obtain informed consent, and to measure outcomes after prostate cancer treatment.
  • We address this issue among underserved, African-American men because of the increased cancer incidence and mortality observed in this population.
  • PATIENTS AND METHODS: We reviewed patient education materials and prostate-specific quality-of-life instruments to identify technical terms describing sexual, urinary, and bowel function.
  • Median literacy level was fourth to sixth grade.
  • Prostate cancer knowledge was poor.
  • CONCLUSION: Limited comprehension of prostate cancer terms and low literacy create barriers to obtaining informed consent for treatment and to measuring prostate cancer outcomes accurately in our study population.
  • In addition, the level of prostate cancer knowledge was poor.
  • These results highlight the need for prostate cancer education efforts and outcomes measurements that consider literacy and use nonmedical language.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Decis Making. 2007 Sep-Oct;27(5):696-713 [17873259.001]
  • [Cites] Ann Intern Med. 2007 Feb 20;146(4):256-65 [17310049.001]
  • [Cites] Ann Intern Med. 2008 Mar 18;148(6):435-48 [18252677.001]
  • [Cites] N Engl J Med. 2008 Mar 20;358(12):1250-61 [18354103.001]
  • [Cites] J Clin Epidemiol. 2005 May;58(5):466-74 [15845333.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1719-24 [10528021.001]
  • [Cites] Urology. 2000 Dec 20;56(6):899-905 [11113727.001]
  • [Cites] Med Decis Making. 2001 Jan-Feb;21(1):37-44 [11206945.001]
  • [Cites] Urology. 2001 Feb;57(2):217-24 [11182324.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):895-8 [11489757.001]
  • [Cites] J Urol. 2001 Sep;166(3):942-6 [11490251.001]
  • [Cites] Ann Intern Med. 2002 Dec 3;137(11):917-29 [12458993.001]
  • [Cites] Med Care. 2003 Jan;41(1):153-64 [12544552.001]
  • [Cites] Urology. 2003 Jan;61(1):2-4 [12559252.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):414-5 [14996868.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] Ann Intern Med. 2004 May 4;140(9):721-8 [15126256.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1358-67 [15367568.001]
  • [Cites] JAMA. 2004 Oct 13;292(14):1711-6 [15479936.001]
  • [Cites] J Fam Pract. 1987 Aug;25(2):176-8 [3612043.001]
  • [Cites] Soc Sci Med. 1989;28(4):339-46 [2705006.001]
  • [Cites] Soc Sci Med. 1991;32(2):193-6 [2014414.001]
  • [Cites] J Urol. 1992 Nov;148(5):1549-57; discussion 1564 [1279218.001]
  • [Cites] JAMA. 1993 May 26;269(20):2650-8 [8487449.001]
  • [Cites] Fam Med. 1993 Jun;25(6):391-5 [8349060.001]
  • [Cites] JAMA. 1994 Sep 14;272(10):773-80 [7521400.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):129-35 [7799493.001]
  • [Cites] Urology. 1995 Jun;45(6):1007-13; discussion 1013-5 [7771002.001]
  • [Cites] Soc Sci Med. 1995 Apr;40(7):903-18 [7792630.001]
  • [Cites] J Fam Pract. 1995 Jul;41(1):33-41 [7798064.001]
  • [Cites] Arch Intern Med. 1996 Jun 24;156(12):1333-6 [8651843.001]
  • [Cites] J Gen Intern Med. 1997 May;12(5):299-305 [9159699.001]
  • [Cites] Ann Intern Med. 1997 Dec 1;127(11):966-72 [9412301.001]
  • [Cites] Can J Public Health. 1997 Sep-Oct;88(5):327-32 [9401168.001]
  • [Cites] Urology. 1997 Dec;50(6):920-8 [9426724.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):275-83 [9440753.001]
  • [Cites] Med Care. 1998 Jul;36(7):1002-12 [9674618.001]
  • [Cites] Am J Med. 1998 Oct;105(4):266-74 [9809686.001]
  • [Cites] JAMA. 1999 Feb 10;281(6):545-51 [10022111.001]
  • [Cites] JAMA. 1999 Feb 10;281(6):552-7 [10022112.001]
  • [Cites] Evid Rep Technol Assess (Summ). 2004 Jan;(87):1-8 [15819598.001]
  • [Cites] Urol Oncol. 2005 May-Jun;23(3):208-15 [15907723.001]
  • [Cites] Med Decis Making. 2005 May-Jun;25(3):290-300 [15951456.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:16 [15963238.001]
  • [Cites] Arch Intern Med. 2006 Jan 9;166(1):7-8 [16401804.001]
  • [Cites] CA Cancer J Clin. 2006 Jan-Feb;56(1):11-25; quiz 49-50 [16449183.001]
  • [CommentIn] J Clin Oncol. 2009 Apr 20;27(12):1938-40 [19307497.001]
  • (PMID = 19307512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA085754; United States / NCI NIH HHS / CA / KO7CA085754
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2669763
  •  go-up   go-down


8. Pruthi RS, Swords K, Schultz H, Carson CC 3rd, Wallen EM: The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. J Urol; 2009 Feb;181(2):574-7; discussion 578
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
  • PURPOSE: The effect of obesity on prostate cancer detection and behavior remains uncertain.
  • MATERIALS AND METHODS: We retrospectively reviewed the records of a consecutive series of 500 men who underwent transrectal ultrasound guided prostate biopsy using a 10 to 12 core biopsy scheme.
  • Variables, including patient age, prostate specific antigen, prostate specific antigen density, digital rectal examination findings, transrectal ultrasound prostate volume and biopsy outcome, including grade, were compared to anthropometric measures, including body mass index.
  • Obese men were younger (62.0 vs 63.8 years), had a larger prostate (57.7 vs 47.8 cc) and were less likely to have any abnormality on digital rectal examination (19.6% vs 30.8%).
  • On statistical modeling for the OR in nonobese vs obese men there was a trend toward lower detection based on crude and age adjusted ORs but not on multivariate OR controlling for age, prostate specific antigen and prostate volume.
  • In addition, when examining for high grade disease (Gleason 4 + 3 or greater), no differences were observed on OR modeling.
  • In men with negative biopsies those who were obese vs nonobese had a larger prostate volume and trended toward a higher median prostate specific antigen and age.
  • CONCLUSIONS: Of men undergoing prostate biopsy using a modern extended biopsy scheme obese men were younger, had a larger prostate and were less likely to have abnormal digital rectal examinations.
  • Although some trends toward a lower detection rate in obese men were observed, such differences were not observed on multivariate analysis, nor were any differences observed in the incidence of higher grade tumors, thus questioning the effect of obesity on prostate cancer detection and behavior in our cases series.
  • [MeSH-major] Biopsy, Needle / methods. Obesity / complications. Prostatic Neoplasms / pathology. Ultrasound, High-Intensity Focused, Transrectal
  • [MeSH-minor] Age Factors. Aged. Analysis of Variance. Body Mass Index. Case-Control Studies. Humans. Immunohistochemistry. Logistic Models. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Prostate-Specific Antigen / blood. Reference Values. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Tumor Burden


9. Loblaw DA, Cheung P: External beam irradiation for localized prostate cancer--the promise of hypofractionation. Can J Urol; 2006 Feb;13 Suppl 1:62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External beam irradiation for localized prostate cancer--the promise of hypofractionation.
  • Within the field of radiation oncology in the last 10 years, there have been two major thematic advances in the understanding and treatment of prostate cancer.
  • The second important discovery was that prostate cancer reacts differently than other tumors to radiation whereby higher doses of radiation per day ("hypofractionated radiation") seem to be more effective in killing prostate cancer cells.
  • The early experience of two hypofractionated trials in intermediate- and high-risk prostate cancer where the equivalent of > 80 Gy (in 2 Gy per day fractions) delivered in 5-6 weeks is reported.
  • In summary, hypofractionated radiation coupled with high-precision techniques may allow for better prostate cancer control rates, shorter treatment times and less toxicity.
  • [MeSH-major] Dose Fractionation. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16526985.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 11
  •  go-up   go-down


10. Cha TL, Qiu L, Chen CT, Wen Y, Hung MC: Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res; 2005 Mar 15;65(6):2287-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
  • Hormone-refractory relapse is an inevitable and lethal event for advanced prostate cancer patients after hormone deprivation.
  • A growing body of evidence indicates that hormone deprivation may promote this aggressive prostate cancer phenotype.
  • This provides a strong rationale for searching new effective agents targeting the down-regulation of AR to treat or prevent advanced prostate cancer progression.
  • Here, we show that emodin, a natural compound, can directly target AR to suppress prostate cancer cell growth in vitro and prolong the survival of C3(1)/SV40 transgenic mice in vivo.
  • Our work indicates a new mechanism for the emodin-mediated anticancer effect and justifies further investigation of emodin as a therapeutic and preventive agent for prostate cancer.
  • [MeSH-major] Androgen Receptor Antagonists. Emodin / pharmacology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Receptors, Androgen / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. EMODIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781642.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA099031; United States / NCI NIH HHS / CA / R01 CA109311
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Receptor Antagonists; 0 / HSP90 Heat-Shock Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Receptors, Androgen; 0 / Ubiquitin; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Mdm2 protein, mouse; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; KA46RNI6HN / Emodin
  •  go-up   go-down


11. Seitz M, Schlenker B, Gratzke C, Weidlich P, Stief CG, Reich O: [Standards for the punch biopsy of the prostate]. MMW Fortschr Med; 2007 Jan 25;149(4):35-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Standards for the punch biopsy of the prostate].
  • If, within the framework of screening examinations for the early detection of cancer of the prostate, the patient wishes a PSA test, the physician should accommodate him, but only after providing comprehensive information about the possible consequences and complications.
  • If a certain threshold value is exceeded, a punch biopsy of the prostate is recommended.
  • This procedure must be performed in accordance with accepted standards to enable, within the diagnostic chain, the reliable detection of a carcinoma of the prostate
  • [MeSH-major] Biomarkers, Tumor / blood. Patient Education as Topic. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Needle. Early Diagnosis. Germany. Humans. Informed Consent. Male. Mass Screening. Postoperative Complications / etiology. Practice Guidelines as Topic


12. Newmark HL, Heaney RP: Dairy products and prostate cancer risk. Nutr Cancer; 2010;62(3):297-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dairy products and prostate cancer risk.
  • Increased calcium intake from dairy products has been suggested as a risk factor for prostate cancer.
  • Several epidemiologic correlations have indicated an increased risk of prostate cancer with long-term, high intake of dairy products in male U.S. physicians and males in Sweden.
  • We propose, however, that the high dietary phosphate of dairy products affects much larger fluctuation in serum phosphate and may be a more likely source of prostate cancer risk from high dietary intake of dairy products.
  • [MeSH-major] Dairy Products / adverse effects. Prostatic Neoplasms / etiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20358466.001).
  • [ISSN] 1532-7914
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium, Dietary; 0 / Phosphates; SY7Q814VUP / Calcium
  • [Number-of-references] 14
  •  go-up   go-down


13. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E: Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. W V Med J; 2005 Jul-Aug;101(4):168-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
  • Since the mid-1980s, permanent prostate brachytherapy has been utilized increasingly as a potentially curative treatment for patients of all ages with clinically localized prostate cancer To determine the 8-year biochemical progression-free survival rate for patients who had undergone monotherapeutic brachytherapy for clinically organ-confined prostate cancer, we conducted a study of 202 patients at Schiffler Cancer Center at Wheeling Hospital in Wheeling, W.Va.
  • These patients had undergone brachytherapy without supplemental external beam radiation therapy or androgen deprivation therapy for clinical T1b-T2c NxM0 (2002 AJCC) prostate cancer from April 1995 through May 2001.
  • Clinical, treatment and dosimetric parameters evaluated for biochemical progression-free survival included patient age, clinical T-stage, Gleason score, pretreatment PSA, risk group, percent positive biopsies, isotope, prostate volume, brachytherapy planning volume, V100/150/200, D90, tobacco status, hypertension and diabetes.
  • [MeSH-major] Brachytherapy / methods. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted
  • [MeSH-minor] Aged. Analysis of Variance. Cohort Studies. Dose-Response Relationship, Radiation. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Proportional Hazards Models. Prostate-Specific Antigen / blood. Radiotherapy Dosage. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome


14. Perner S, Schmidt FH, Hofer MD, Kuefer R, Rubin M: [TMPRSS2-ETS gene fusion in prostate cancer]. Urologe A; 2007 Jul;46(7):754-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [TMPRSS2-ETS gene fusion in prostate cancer].
  • By analogy, fusion status in prostate cancer may determine clinical outcome and secondary genetic alterations as witnessed in Ewing's tumors.
  • MATERIAL: These novel gene fusions occur in the majority of prostate cancers identified by PSA screening and are the driving mechanism for overexpression of the three members of the ETS transcription factor family, either ERG (21q22.3), ETV1 (7p21.2), or ETV4 (17q21).
  • Considering the high incidence of prostate cancer and the high frequency of this gene fusion, the TMPRSS2-ETS gene fusion is the most common genetic aberration so far described in human malignancies.
  • Also similar to the Philadelphia chromosome in chronic myelogenous leukemia (CML), the gene fusion in prostate cancer has potential as an important candidate for the development of targeted therapy.
  • [MeSH-major] Biomarkers, Tumor / genetics. Neoplasm Proteins / genetics. Oncogene Fusion / genetics. Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / genetics. Proto-Oncogene Proteins c-ets / genetics. Serine Endopeptidases / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10658-63 [17108102.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3396-400 [16585160.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Nov;45(11):1018-32 [16897747.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Feb;45(2):154-63 [16235241.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Eur Urol. 2003 Jul;44(1):8-15; discussion 15-6 [12814669.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10242-6 [17079440.001]
  • [Cites] Neoplasia. 2006 Oct;8(10 ):885-8 [17059688.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):465-9 [16820092.001]
  • [Cites] Oncogene. 2003 Feb 27;22(8):1247-52 [12606952.001]
  • [Cites] Cancer Biol Ther. 2007 Jan;6(1):40-5 [17172822.001]
  • [Cites] J Clin Pathol. 2007 Nov;60(11):1238-43 [17259299.001]
  • [Cites] J Histochem Cytochem. 1991 Sep;39(9):1221-6 [1918940.001]
  • [Cites] Mod Pathol. 2007 May;20(5):538-44 [17334343.001]
  • [Cites] Lab Invest. 2006 Nov;86(11):1099-102 [16983328.001]
  • [Cites] Oncogene. 2005 May 26;24(23 ):3847-52 [15750627.001]
  • [Cites] Neoplasia. 2006 Oct;8(10 ):826-32 [17032499.001]
  • [Cites] Oncogene. 2007 Apr 19;26(18):2667-73 [17043636.001]
  • [Cites] J Pathol. 2007 May;212(1):91-101 [17385188.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8347-51 [16951141.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4596-9 [17237811.001]
  • (PMID = 17458530.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-ets; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / TMPRSS2 protein, human
  • [Number-of-references] 24
  •  go-up   go-down


15. Lawson DA, Xin L, Lukacs R, Xu Q, Cheng D, Witte ON: Prostate stem cells and prostate cancer. Cold Spring Harb Symp Quant Biol; 2005;70:187-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate stem cells and prostate cancer.
  • Understanding prostate stem cells (PSCs) may provide insight for the design of therapeutics for prostate cancer.
  • We have developed a quantitative in vivo colony-forming assay and have demonstrated that the Sca-1 antigen is present on the surface of a prostate cell subpopulation that possesses multiple stem cell properties.
  • Immunofluorescent analysis demonstrates that Sca-1 is expressed by both basal and luminal cells in the proximal region of the adult prostate, but is not expressed by either lineage in more distal regions.
  • Sca-1 is also expressed by nearly all cells within fetal prostate epithelial chords, suggesting Sca-1 may be conserved on PSCs throughout development.
  • Malignant epithelial cells from TRAMP mice, as well as normal prostate cells with lentiviral-mediated alteration of the PTEN/AKT signaling pathway, give rise to PIN lesions and prostate cancer in vivo.
  • Alteration of PTEN/AKT signaling in Sca-1-enriched PSCs also results in PIN lesions, suggesting that PSCs can serve as one target for prostate carcinogenesis.
  • [MeSH-major] Neoplastic Stem Cells / pathology. Prostate / cytology. Prostatic Neoplasms / pathology. Stem Cells / cytology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16869753.001).
  • [ISSN] 0091-7451
  • [Journal-full-title] Cold Spring Harbor symposia on quantitative biology
  • [ISO-abbreviation] Cold Spring Harb. Symp. Quant. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA09056
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Ly; 0 / Ly6a protein, mouse; 0 / Membrane Proteins; 0 / Transforming Growth Factor beta; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / Pten protein, mouse; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


16. Davidson DD, Koch MO, Lin H, Jones TD, Biermann K, Cheng L: Does the size matter?: Prostate weight does not predict PSA recurrence after radical prostatectomy. Am J Clin Pathol; 2010 Apr;133(4):662-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the size matter?: Prostate weight does not predict PSA recurrence after radical prostatectomy.
  • Previous studies suggest that low prostate weight is a significant negative prognostic factor for prostate cancer.
  • In the current study, the data for 431 men who underwent radical retropubic prostatectomy between 1990 and 1998 were analyzed for association between prostate weight and various clinical and pathologic parameters.
  • These included age, preoperative prostate-specific antigen (PSA) level, PSA recurrence, pathologic stage, Gleason grade, extraprostatic extension, positive surgical margins, tumor volume, associated high-grade prostatic intraepithelial neoplasia, perineural invasion, and lymph node metastasis.
  • A significant positive correlation was found between prostate weight and increasing patient age or increasing preoperative PSA level.
  • There was no significant independent association between prostate weight and any of the other variables examined.
  • No association was found between prostate weight and PSA recurrence.
  • Although increasing prostate weight correlates with increased patient age and higher preoperative PSA level, it does not independently predict postoperative cancer recurrence.
  • [MeSH-major] Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / pathology


17. Finne P, Fallah M, Hakama M, Ciatto S, Hugosson J, de Koning H, Moss S, Nelen V, Auvinen A: Lead-time in the European Randomised Study of Screening for Prostate Cancer. Eur J Cancer; 2010 Nov;46(17):3102-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lead-time in the European Randomised Study of Screening for Prostate Cancer.
  • BACKGROUND: Lead-time is defined as the time by which screening advances the diagnosis compared with absence of screening.
  • A sufficiently long lead-time needs to be achieved so that cancer can be detected while still curable.
  • MATERIAL AND METHODS: In the first screening round, a total of 56,294 men aged 55-74 years were screened with serum prostate specific antigen (PSA) in five countries of the European Randomised Study of Screening for Prostate Cancer (ERSPC) with an overall detection rate (prevalence) of 2.8% (1972 prostate cancers).
  • Prostate cancer incidence among 92,142 men randomly allocated to the control arm of the trial was also assessed.
  • Lead-time was estimated as the time required to accumulate a similar cumulative risk of prostate cancer in the control arm to the detection rate in the intervention arm, i.e. from the ratio of detection rate (prevalence of screen-detected cases) and expected incidence (cumulative risk).
  • Lead-time based on advanced prostate cancer only was slightly shorter, mean 5.3 years (95% CI 4.6-6.0).
  • CONCLUSION: The lead-time for prostate cancer found in ERSPC substantially exceeded that found for breast, cervical and colorectal cancer screening.
  • One round of prostate cancer screening can advance clinical diagnosis by 4-8 years.
  • [MeSH-major] Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Clinical Protocols. Early Detection of Cancer / methods. Europe / epidemiology. Humans. Incidence. Male. Middle Aged. Prostate-Specific Antigen / blood. Risk Assessment. Time Factors

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Ltd.
  • (PMID = 21047593.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


18. Butler LM, Wang R, Wong AS, Koh WP, Yu MC: Cigarette smoking and risk of prostate cancer among Singapore Chinese. Cancer Causes Control; 2009 Dec;20(10):1967-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking and risk of prostate cancer among Singapore Chinese.
  • Prospective epidemiologic studies conducted in Western populations support an association between current smoking and aggressive subtypes of prostate cancer.
  • In Singapore, where prostate-specific antigen is not used for population-wide screening, prostate cancer incidence has tripled within the past two decades.
  • Using Cox regression methods, we examined the relationship between smoking and prostate cancer established between 1993 and 1998 in a cohort of 27,293 Singapore Chinese men.
  • As of December 2006, 250 incident prostate cancer cases were diagnosed.
  • Smoking was not a major risk factor for prostate cancer in our Singapore Chinese cohort, a traditionally low risk population with parallel increases in incidence and mortality.
  • [MeSH-major] Asian Continental Ancestry Group / ethnology. Carcinoma / etiology. Prostatic Neoplasms / etiology. Smoking / adverse effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579052.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA55069; United States / NCI NIH HHS / CA / R35 CA53890
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


19. Fowler JF: The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol; 2005;44(3):265-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
  • These differences work the opposite way round for prostate tumors versus late complications compared with most other types of tumor.
  • Using the Linear-Quadratic formula it is aimed to explain these differences, especially for treatments of prostate cancer.
  • The unusually slow growth rate of prostate cancers is associated with their high sensitivity to increased fraction size, so a large number of small fractions, such as 35 or 40 "daily" doses of 2 Gy, is not an optimum treatment.
  • Theoretical modeling shows a stronger enhancement of tumor effect than of late complications for larger (and fewer) fractions, in prostate tumors uniquely.
  • Biologically Effective Doses and Normalized Total Doses (in 2 Gy fraction equivalents) are given for prostate tumor, late rectal reactions, and--a new development--acute rectal mucosa.
  • Tables showing the change of fraction-size sensitivity (the alpha/beta ratio) with proliferation rates of tissues lead to the association of slow cell doubling times in prostate tumors with small alpha/beta ratios.
  • The alpha/beta ratios of prostate tumors appear to be as low as 1.5 Gy (95% confidence interval 1.3-1.8 Gy), in contrast with the value of about 10 Gy for most other types of tumor.
  • Monotherapy by brachytherapy for low-risk cancer prostate using two to four fractions in a few days can give even higher biological effects on the tumors.
  • [MeSH-major] Dose Fractionation. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076699.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 31
  •  go-up   go-down


20. Surapaneni KM, Venkata GR: Lipid peroxidation and antioxidant status in patients with carcinoma of prostate. Indian J Physiol Pharmacol; 2006 Oct-Dec;50(4):350-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid peroxidation and antioxidant status in patients with carcinoma of prostate.
  • Prostate cancer is the most prevalent cancer found in men above the age of fifty years and is frequently diagnosed in men between 45 and 89 years of age with a median age of 72 years.
  • This work was undertaken to assess oxidative stress and anti oxidant status in patients with carcinoma of prostate.
  • Glutathione (GSH), Malondialdehyde (MDA), Super Oxide Dismutase (SOD) levels in Erythrocytes and plasma Glutathione-S-Transferase (GST) levels were estimated in patients with carcinoma of prostate and compared to controls.
  • It was observed that Erythrocyte GSH levels were significantly lower and Erythrocyte MDA & SOD levels were significantly higher in patients with carcinoma of prostate compared to controls.
  • Oxidative stress may be involved in prostate cancer as evidenced by the higher MDA levels and lower GSH levels.
  • [MeSH-major] Antioxidants / metabolism. Lipid Peroxidation / physiology. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17402264.001).
  • [ISSN] 0019-5499
  • [Journal-full-title] Indian journal of physiology and pharmacology
  • [ISO-abbreviation] Indian J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Thiobarbituric Acid Reactive Substances; 4Y8F71G49Q / Malondialdehyde; EC 1.15.1.1 / Superoxide Dismutase; EC 2.5.1.18 / Glutathione Transferase; GAN16C9B8O / Glutathione
  •  go-up   go-down


21. Lowe JF, Frazee LA: Update on prostate cancer chemoprevention. Pharmacotherapy; 2006 Mar;26(3):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on prostate cancer chemoprevention.
  • BACKGROUND: Prostate cancer is the most common type of cancer and the second leading cause of cancer-related deaths in American men.
  • Its high rate of occurrence and long lead time to clinically significant disease make prostate cancer an ideal disease for pharmacologic or nutritional chemoprevention.
  • METHODS: To identify the various chemoprevention strategies for prostate cancer, a MEDLINE search (from 1967-2005) and bibliographic search of the English-language literature were conducted.
  • RESULTS: Epidemiologic and retrospective studies have assessed the effect of carotenoids (e.g., lycopene), vitamins, selenium, and nonsteroidal antiinflammatory drugs (NSAIDs) on the rate of occurrence of prostate cancer.
  • The few published prospective trials evaluated prostate cancer as a secondary end point.
  • Lycopene (as beta-carotene) and selenium supplementation have been associated with a reduced risk of prostate cancer in nested case-control studies, but only in subgroups of men with low baseline plasma lycopene (or beta-carotene) and selenium levels respectively.
  • The Prostate Cancer Prevention Trial prospectively evaluated finasteride, a 5-alpha-reductase inhibitor, as chemoprevention.
  • The results showed a 25% relative risk reduction in prostate cancer, albeit at an increased risk of invasive tumors.
  • CONCLUSION: Data regarding lycopene, vitamin E, and selenium as chemoprevention for prostate cancer appear promising.
  • Prospective trials such as the Selenium and Vitamin E Cancer Prevention Trial (SELECT) will clarify the role of these agents in prostate cancer prevention.
  • Although finasteride has decreased overall prostate cancer occurrence, the risk of invasive tumors may outweigh the benefit of this agent.
  • The continuing Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial may help define a role for the 5-alpha-reductase inhibitors in cancer chemoprevention.
  • At this time, nothing has been proven effective as chemoprevention against clinically significant prostate cancer.
  • [MeSH-major] Prostatic Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pharmacotherapy. 2006 Oct;26(10):1533; author reply 1533 [16999665.001]
  • (PMID = 16503715.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Azasteroids; 0 / Enzyme Inhibitors; 0 / Vitamins; 1406-18-4 / Vitamin E; 36-88-4 / Carotenoids; 57GNO57U7G / Finasteride; H6241UJ22B / Selenium; O0J6XJN02I / Dutasteride
  • [Number-of-references] 48
  •  go-up   go-down


22. Ishkanian AS, Zafarana G, Thoms J, Bristow RG: Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncol; 2010 Oct;49(7):888-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
  • Prostate cancer is the most common male cancer and up to one fifth of diagnosed patients will die of their disease.
  • Current prognostic variables including T-category (of the TNM staging), the absolute or kinetics of prostatic specific antigen (PSA) and the pathologic Gleason score (GS) are utilized to place men in low, intermediate and high-risk prostate cancer risk groupings.
  • Somatic alterations in prostate cancer.
  • Herein, we review the potential for somatic alterations in tumor-associated genes (based on comparative genomic hybridization (CGH) in prostate cancers to be novel prognostic, and possibly predictive, factors for prostate cancer radiotherapy response.
  • Intermediate risk prostate cancers show alterations in a number of genes thought to be involved in radiosensitivity, DNA repair, cell death and stem cell renewal.
  • Conclusions. The use of high-resolution CGH for fine-mapping of deletions and amplifications in pre-radiotherapy prostate cancer biopsies is feasible.
  • Genetic alterations may delineate localized prostate cancer from systemic disease and be used as a predictive factor in that patients would be individually triaged to local (surgery versus radiotherapy) and/or adjuvant (adjuvant androgen ablation or post-operative radiotherapy) therapies in a prospective fashion to improve outcome.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / radiotherapy. Comparative Genomic Hybridization / methods. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / radiotherapy


23. Braeckman J, Autier P, Garbar C, Marichal MP, Soviany C, Nir R, Nir D, Michielsen D, Bleiberg H, Egevad L, Emberton M: Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int; 2008 Feb;101(3):293-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer.
  • OBJECTIVE: To assess the extent to which prostate HistoScanning (PHS), a new ultrasound-based technology that uses computer-aided analysis to quantify tissue disorganization induced by malignant processes, can identify and characterize foci of prostate cancer compared with step-sectioned radical prostatectomy (RP) specimens.
  • In 13 men the histology was examined on sections of the whole-mount prostate onto which a grid of 5 x 5 mm squares was applied.
  • In the same set of data, EPE was attributed to one prostate cancer that on pathological inspection was deemed to be organ-confined (pT2b).
  • CONCLUSIONS: PHS has the potential to identify and characterize prostate cancer foci noninvasively.
  • The precision appears to be sufficient to suggest that PHS might be useful as a triage test for men deemed to be at risk of prostate cancer and who wish to avoid prostate biopsy.
  • [MeSH-major] Image Interpretation, Computer-Assisted / standards. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / ultrasonography


24. Nair TM: On selecting mRNA isoform features for profiling prostate cancer. Comput Biol Chem; 2009 Dec;33(6):421-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On selecting mRNA isoform features for profiling prostate cancer.
  • In our earlier study we had used mRNA isoforms expression to identify biomarkers for prostate cancer (Li et. al, 2006.
  • Cancer Res. 66 (8) 4079-4088).
  • Further, we have rigorously analyzed the isoform expression data to understand the variability and heterogeneity associated with the expression levels between (i) prostate cancer cell lines and non-prostate cancer cell lines and (ii) normal prostate tissue and prostate cancer tissue.
  • [MeSH-major] Gene Expression Profiling. Prostatic Neoplasms / genetics. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19889581.001).
  • [ISSN] 1476-928X
  • [Journal-full-title] Computational biology and chemistry
  • [ISO-abbreviation] Comput Biol Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RNA, Messenger
  •  go-up   go-down


25. Bradley SV, Oravecz-Wilson KI, Bougeard G, Mizukami I, Li L, Munaco AJ, Sreekumar A, Corradetti MN, Chinnaiyan AM, Sanda MG, Ross TS: Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res; 2005 May 15;65(10):4126-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer.
  • Huntingtin-interacting protein 1 (HIP1) is frequently overexpressed in prostate cancer.
  • In addition to human cancers, HIP1 is also overexpressed in prostate tumors from the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model.
  • In addition, we report that autoantibodies to HIP1 developed in the sera of TRAMP mice with prostate cancer as well as in the sera from human prostate cancer patients.
  • This led to the development of an anti-HIP1 serum test in humans that had a similar sensitivity and specificity to the anti-alpha-methylacyl CoA racemase (AMACR) and prostate-specific antigen tests for prostate cancer and when combined with the anti-AMACR test yielded a specificity of 97%.
  • These data suggest that HIP1 plays a functional role in tumorigenesis and that a positive HIP1 autoantibody test may be an important serum marker of prostate cancer.
  • [MeSH-major] Adenocarcinoma / immunology. Autoantibodies / blood. DNA-Binding Proteins / immunology. Prostatic Neoplasms / immunology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899803.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098730-02; United States / NCI NIH HHS / CA / R01 CA82419-01; United States / NCI NIH HHS / CA / R01-CA82363-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / DNA-Binding Proteins; 0 / HIP1 protein, human
  •  go-up   go-down


26. Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, Emami M, Daigneault L, Panchal C, Sugar L, Jewett MA, Narod SA: A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol; 2006 Apr;175(4):1291-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
  • PURPOSE: New biomarkers for prostate cancer are needed.
  • MATERIALS AND METHODS: We conducted a case-control study of 1,212 men with no previous history of prostate cancer and who underwent a prostate biopsy from 1998 to 2000 because of an increased PSA or an abnormal DRE.
  • Cases were patients with prostate cancer, and controls were patients who had no evidence of cancer.
  • Multivariate logistic regression analysis was used to determine whether or not PSP94 levels improved the predictive value for prostate cancer.
  • RESULTS: Of the 1,212 men 596 (49.2%) had cancer detected.
  • The adjusted odds ratios for the presence of prostate cancer for patients with the lowest quartile of PSP94, compared to patients in the highest quartile was 2.70 (95% CI 1.8 - 4.0, p <0.0001).
  • Among a subgroup of 649 men in whom PSA had a low predictive value (PSA less than 20 ng/ml, normal DRE and less than 70 years), 260 (40.1%) were found to have cancer.
  • In this subgroup total PSP94 levels helped discriminate between patients with high grade disease (Gleason score 8 or more, median 1.90 ng/ml), moderate grade disease (Gleason score 7, median 2.34 ng/ml) and low grade disease (Gleason score 6 or less, median 2.60 ng/ml, p = 0.007).
  • CONCLUSIONS: Patients with low total PSP94 levels had a high probability for having prostate cancer detected at biopsy.
  • The total PSP94 level was able to help identify patients with high grade disease among a subset of patients in whom PSA and FTPSA are least informative.
  • [MeSH-major] Biomarkers, Tumor / blood. Follicle Stimulating Hormone / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology. Prostatic Secretory Proteins / blood


27. Chiang CF, Son EL, Wu GJ: Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis. Prostate; 2005 Sep 1;64(4):408-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis.
  • BACKGROUND: We used the TRAMP mouse model for testing the effect of oral doxazosin treatment on the in vivo prostate tumor growth and metastasis.
  • The levels of MUC18, Bcl-2, Bax, caspase-3, poly (ADP-ribose) polymerase (PARP), phospho (Ser473)-AKT, and Ki-67 in the mouse prostate tumors were determined.
  • RESULTS: Oral treatment of the TRAMP mice with doxazosin for 45-81 days did not decrease the size of preexisting prostate tumors, but it limited the metastasis to peri-aortic lymph nodes.
  • A prolonged treatment of TRAMP mice with doxazosin (156-196 days), if administered early, decreased the prostate tumor weight and completely suppressed metastasis.
  • The doxazosin treatment did not further decrease the expression of an already low level of Bcl-2 in all prostate tumors, but it increased the expression of Bax, and the activation of caspase-3, and the cleavage of a downstream substrate, PARP.
  • The treatment in the early phase appeared to promote prostate tumor growth and increased the expression of a proliferative index, Ki-67.
  • CONCLUSIONS: Doxazosin, if administered early, may be useful for preventing the prostate tumor formation, and also for limiting or completely suppressing the metastasis of prostate cancer in the TRAMP model.
  • [MeSH-major] Adrenergic alpha-Antagonists / pharmacology. Doxazosin / pharmacology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15789364.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Androgen-Binding Protein; 0 / Antigens, CD; 0 / Antigens, CD146; 0 / Bax protein, mouse; 0 / Ki-67 Antigen; 0 / Mcam protein, mouse; 0 / Neural Cell Adhesion Molecules; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 0 / probasin; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; NW1291F1W8 / Doxazosin
  •  go-up   go-down


28. Zhang P, Zheng Y, Ran H, Leng Z, Wang Z: Case report: gastric adenocarcinoma metastatic to the prostate gland. J Radiol Case Rep; 2010;4(3):35-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: gastric adenocarcinoma metastatic to the prostate gland.
  • Metastasis to the prostate gland from gastric cancer is exceedingly rare.
  • We have presented a rare case of gastric malignancy metastasizing to the prostate diagnosed by transrectal ultrasound guided prostate biopsy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22470718.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303380
  • [Keywords] NOTNLM ; gastric adenocarcinoma / metastases / secondary prostatic cancer / transrectal ultrasound
  •  go-up   go-down


29. Galić J, Simunović D: Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia. Coll Antropol; 2008 Dec;32(4):1195-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia.
  • The objective of our study was to investigate the prevalence of prostate disease in general male population.
  • The prevalence of benign prostate hyperplasia was 23.1%, of prostatitis 5.1% and of prostate cancer 3.7%, which is within expected reported values.
  • Significant lower urinary tract symptoms were found in both subjects with benign prostate hyperplasia and prostatitis, showing a strong overlap of symptoms.
  • The results indicate that alcohol abuse is strongly related to subjects with prostate cancer, although this relation is not confirmed by all authors.
  • On the hormonal scale we found higher levels of binned testosterone in our subjects with prostate cancer, what is disproved by some authors.
  • Estrogen is found in higher levels and recent reports are showing higher levels of estrogen metabolites in prostate cancer subjects.
  • Also we found lower levels of vitamin D in subjects with benign prostate hyperplasia and prostate cancer.
  • Since vitamin D is known to inhibit cellular proliferation, lower levels are confirmatory, with its loss of protective role against prostate cancer.
  • Our results suggest that male population in Croatia (at least in Slavonia) with prostate diseases is, with all findings taken into account, within limits as compared to populations in developed European countries, but on a lower border.
  • [MeSH-major] Hormones / blood. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / epidemiology. Prostatic Neoplasms / blood. Prostatic Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Hormones.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19149228.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Hormones
  •  go-up   go-down


30. Tamura K, Furihata M, Chung SY, Uemura M, Yoshioka H, Iiyama T, Ashida S, Nasu Y, Fujioka T, Shuin T, Nakamura Y, Nakagawa H: Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci; 2009 May;100(5):914-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.
  • Prostate cancer is usually androgen-dependent and responds well to androgen ablation therapy based on castration.
  • However, at a certain stage some prostate cancers eventually acquire a castration-resistant phenotype where they progress aggressively and show very poor response to any anticancer therapies.
  • To characterize the molecular features of these clinical castration-resistant prostate cancers, we previously analyzed gene expression profiles by genome-wide cDNA microarrays combined with microdissection and found dozens of trans-activated genes in clinical castration-resistant prostate cancers.
  • Among them, we report the identification of a new biomarker, stanniocalcin 2, as an overexpressed gene in castration-resistant prostate cancer cells.
  • Real-time polymerase chain reaction and immunohistochemical analysis confirmed overexpression of stanniocalcin 2, a 302-amino-acid glycoprotein hormone, specifically in castration-resistant prostate cancer cells and aggressive castration-naïve prostate cancers with high Gleason scores (8-10).
  • The gene was not expressed in normal prostate, nor in most indolent castration-naïve prostate cancers.
  • Knockdown of stanniocalcin 2 expression by short interfering RNA in a prostate cancer cell line resulted in drastic attenuation of prostate cancer cell growth.
  • Concordantly, stanniocalcin 2 overexpression in a prostate cancer cell line promoted prostate cancer cell growth, indicating its oncogenic property.
  • These findings suggest that stanniocalcin 2 could be involved in aggressive phenotyping of prostate cancers, including castration-resistant prostate cancers, and that it should be a potential molecular target for development of new therapeutics and a diagnostic biomarker for aggressive prostate cancers.
  • [MeSH-major] Castration. Glycoproteins / metabolism. Intercellular Signaling Peptides and Proteins / metabolism. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298603.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / STC2 protein, human
  •  go-up   go-down


31. Mann MJ, DeCastro GJ, Desai M, Benson MC, McKiernan JM: Predictive significance of surgical margin status after prostatectomy for prostate cancer during PSA era. Urology; 2008 Dec;72(6):1203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive significance of surgical margin status after prostatectomy for prostate cancer during PSA era.
  • OBJECTIVES: The presence of positive surgical margins (PSMs) after prostatectomy for prostate cancer has long been an indicator of poor survival outcomes.
  • However, with the downstaging of cancer occurring in the prostate-specific antigen testing era, we sought to determine whether the risk associated with PSMs retains the same effect on prognosis as before the prostate-specific antigen testing era.
  • RESULTS: The median age, preoperative prostate-specific antigen, and Gleason score was 61.6 years, 6 ng/mL, and 7, respectively, and >50% of patients had pathologic Stage T2 disease.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatectomy / methods. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Male. Medical Oncology / methods. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Predictive Value of Tests. Prognosis. Risk Factors. Treatment Outcome


32. Hori J, Okuyama M, Azumi M, Kato Y, Saga Y, Hashimoto H, Tokumitsu M, Kakizaki H: [Indication of repeat prostate biopsy for the diagnosis of prostate cancer]. Hinyokika Kiyo; 2006 Nov;52(11):835-8; discussion 838-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication of repeat prostate biopsy for the diagnosis of prostate cancer].
  • There is no standard criterion for repeat prostate biopsy in cases with a negative initial biopsy.
  • We retrospectively analyzed our experience of repeat prostate biopsy to establish its indication for the diagnosis of prostate cancer.
  • From April 1997 to March 2005, 35 consecutive patients underwent repeat prostate biopsy at the department of Urology, Asahikawa Medical College Hospital because of clinically suspicious prostate cancer despite a negative initial biopsy.
  • We compared patients' age, number of cores obtained during repeat biopsy, digital rectal examination findings, total prostate volume, the time from the first to the last biopsy, total prostate specific antigen (PSA) value, free PSA/total PSA ratio, PSA density and PSA velocity between cancer-positive and cancer-negative groups.
  • Prostate cancer was detected in 17 of 35 patients (49%).
  • Fifteen patients with prostate cancer were diagnosed by the first repeat biopsy and other 2 patients were diagnosed by the second repeat biopsy.
  • Persistently elevated total PSA and a higher PSA density in cases with a negative initial biopsy might be a good indication of repeat prostate biopsy for the diagnosis of prostate cancer.
  • [MeSH-major] Biopsy. Prostate / pathology. Prostatic Neoplasms / pathology


33. Wang LG, Chiao JW: Prostate cancer chemopreventive activity of phenethyl isothiocyanate through epigenetic regulation (review). Int J Oncol; 2010 Sep;37(3):533-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer chemopreventive activity of phenethyl isothiocyanate through epigenetic regulation (review).
  • Prostate cancer is one of the most commonly diagnosed cancers in men.
  • Therefore, finding strategies for the prevention of prostate cancer initiation and disease progression is a medical challenge.
  • Consumption of cruciferous vegetables has been reported to be associated with reduced incidence of prostate cancer cases.
  • In this review, we summarize the recent findings of PEITC on prostate cancer prevention with an emphasis on epigenetic mechanisms.
  • The gene for detoxifying enzyme pi-class glutathione S-transferase (GSTP1), silenced in the vast majority of prostate tumor cells, could be reactivated and the enzymatic function recovered.
  • The epigenetic regulation may play a critical role, along with interactive mechanisms including the disruption of microtubule polymerization, in prostate cancer prevention by PEITC.
  • Inhibiting and eliminating cancer cells forms the basis of cancer prevention.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Isothiocyanates / pharmacology. Prostatic Neoplasms / genetics. Prostatic Neoplasms / prevention & control


34. Ellinger J, Bastian PJ, Biermann K, Schmidt ME, Textor J, Bollmann D, Zhou H, Müller SC: Prostate cancer tissue is masked by bicalutamide: a case report. Eur J Med Res; 2007 May 29;12(5):212-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer tissue is masked by bicalutamide: a case report.
  • Prostate cancer is the most common malignant tumor in men.
  • In this case, local recurrence was confirmed by needle biopsy in a patient five years following radical prostatectomy for prostate adenocarcinoma.
  • Despite of detailed histological work-up and immunohistochemistry cancer suspicious lesions were not found.
  • We think that bicalutamide may be capable of masking prostate cancer cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / adverse effects. Anilides / adverse effects. Neoplasm Recurrence, Local / pathology. Nitriles / adverse effects. Prostatic Neoplasms / drug therapy. Tosyl Compounds / adverse effects
  • [MeSH-minor] Biopsy, Needle. Humans. Immunohistochemistry. Male. Middle Aged. Neoadjuvant Therapy. Prostate / drug effects. Prostate-Specific Antigen / blood. Prostatectomy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17513193.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


35. Drott JB, Alexeyev O, Bergström P, Elgh F, Olsson J: Propionibacterium acnes infection induces upregulation of inflammatory genes and cytokine secretion in prostate epithelial cells. BMC Microbiol; 2010;10:126
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Propionibacterium acnes infection induces upregulation of inflammatory genes and cytokine secretion in prostate epithelial cells.
  • BACKGROUND: The immune stimulating bacterium Propionibacterium acnes is a frequent colonizer of benign and malignant prostate tissue.
  • To understand the pathogenesis of the earliest phase of this infection, we examined the P. acnes triggered immune response in cultivated prostate epithelial cells.
  • RESULTS: Prostate epithelial cells are triggered to secrete IL-6, IL-8 and GM-CSF when infected with P. acnes.
  • CONCLUSIONS: P. acnes has potential to trigger a strong immune reaction in the prostate glandular epithelium.
  • Upon infection of prostate via the retrograde urethral route, the induced inflammatory reaction might facilitate bacterial colonization deeper in the prostate tissue where persistent inflammation may impact the development of prostate diseases as hyperplasia and/or malignancy.
  • [MeSH-major] Cytokines / secretion. Epithelial Cells / immunology. Epithelial Cells / microbiology. Gram-Positive Bacterial Infections / immunology. Propionibacterium acnes / immunology. Prostate / microbiology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Oct;164(4):1221-8 [10992370.001]
  • [Cites] Urology. 2009 Feb;73(2):220-4 [18407335.001]
  • [Cites] J Urol. 2000 Jan;163(1):127-30 [10604329.001]
  • [Cites] J Pathol. 2000 Jul;191(3):239-44 [10878544.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2159-65 [11733366.001]
  • [Cites] J Dermatol Sci. 2002 Aug;29(2):97-103 [12088610.001]
  • [Cites] Trends Immunol. 2002 Aug;23(8):403-8 [12133803.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):655-63 [12547723.001]
  • [Cites] Annu Rev Immunol. 2003;21:335-76 [12524386.001]
  • [Cites] J Clin Invest. 2004 May;113(10):1473-81 [15146245.001]
  • [Cites] Infect Immun. 1985 Jul;49(1):116-21 [2989178.001]
  • [Cites] J Invest Dermatol. 1991 Jul;97(1):73-9 [1711550.001]
  • [Cites] Infect Immun. 1995 Aug;63(8):3158-65 [7542639.001]
  • [Cites] Annu Rev Immunol. 2005;23:1-21 [15771564.001]
  • [Cites] J Urol. 2005 Jun;173(6):1969-74 [15879794.001]
  • [Cites] J Cell Biochem. 2005 Jun 1;95(3):497-505 [15838876.001]
  • [Cites] Dermatology. 2005;211(3):193-8 [16205063.001]
  • [Cites] Br J Dermatol. 2005 Dec;153(6):1105-13 [16307644.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):386-91 [16302262.001]
  • [Cites] J Leukoc Biol. 2006 May;79(5):989-98 [16522744.001]
  • [Cites] Cancer Causes Control. 2006 Nov;17(9):1127-33 [17006718.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):7-11 [17420288.001]
  • [Cites] Urol Oncol. 2007 May-Jun;25(3):242-9 [17483023.001]
  • [Cites] Urol Oncol. 2007 May-Jun;25(3):250-9 [17483024.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6854-62 [17638896.001]
  • [Cites] J Med Microbiol. 2007 Aug;56(Pt 8):1025-32 [17644708.001]
  • [Cites] Urol Oncol. 2007 Sep-Oct;25(5):398-400 [17826659.001]
  • [Cites] J Clin Microbiol. 2007 Nov;45(11):3721-8 [17881550.001]
  • [Cites] Prostate. 2008 Feb 1;68(2):223-9 [18092352.001]
  • [Cites] Prostate. 2008 Feb 15;68(3):306-20 [18163428.001]
  • [Cites] J Cell Biochem. 2008 Apr 1;103(5):1344-53 [17955503.001]
  • [Cites] Carcinogenesis. 2008 Jun;29(6):1148-56 [18487223.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6735-41 [18980965.001]
  • [Cites] J Cell Biochem. 2008 Nov 1;105(4):931-9 [18655194.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2941-8 [11555613.001]
  • (PMID = 20420679.001).
  • [ISSN] 1471-2180
  • [Journal-full-title] BMC microbiology
  • [ISO-abbreviation] BMC Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  • [Other-IDs] NLM/ PMC2867951
  •  go-up   go-down


36. Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, Catalona WJ: Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? J Urol; 2007 Jan;177(1):102-6; discussion 106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
  • PURPOSE: Several studies suggest that obesity may be associated with more aggressive prostate cancer.
  • Similarly the rate of serum prostate specific antigen change is associated with adverse tumor features and prostate cancer specific mortality rates after radical prostatectomy and radiation therapy.
  • We examined the associations among obesity, prostate specific antigen velocity and adverse tumor features in men treated with radical prostatectomy.
  • Prostate specific antigen velocity and other clinicopathological features were compared among men with a body mass index of less than 25, 25 to 29.9 and 30 or greater.
  • RESULTS: Although Gleason score and prostate volume were similar among groups, there was a significantly lower proportion with organ confined disease and fewer low volume tumors as body mass index increased.
  • Of patients with a body mass index of 30 or greater 52% had a preoperative prostate specific antigen velocity of more than 2 ng/ml yearly compared to 34% with a body mass index of 25 to 29.9 and 26% with a body mass index of less than 25 (p = 0.04).
  • Nevertheless, obesity was significantly associated with increased preoperative prostate specific antigen velocity.
  • Additional studies are needed to further clarify the links between body mass index, prostate specific antigen velocity and prostate cancer progression, and determine whether weight reduction could lead to improved outcomes.
  • [MeSH-major] Body Mass Index. Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162013.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


37. Begley LA, Kasina S, MacDonald J, Macoska JA: The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine; 2008 Aug;43(2):194-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy.
  • Benign Prostatic Hypertrophy (BPH, also known as benign prostatic hyperplasia or benign prostatic enlargement), is one of the most common benign proliferative conditions associated with aging in men and is pathologically characterized by the proliferation of fibroblast/myofibroblast and epithelial cell types in the prostate.
  • Previous studies from our laboratory have shown that the CXC-type chemokines, CXCL5 and CXCL12, are secreted by aging prostate stroma and promote both proliferative and transcriptional responses from prostate epithelial cells.
  • Using array-based gene expression profiling and quantitative reverse-transcriptase polymerase chain reaction, we now show that the transcriptome of the aging prostate stroma is characterized by the up-regulation of several genes that encode secreted inflammatory mediators, including secreted CXC-type chemokines (CXCL1, CXCL2, CXCL5, CXCL6, CXCL12), interleukins (IL11, IL33), and transcripts with cytokine homology (CYTL1).
  • At the protein level, ELISA experiments demonstrated that CXCL1, CXCL5, and CXCL6 were secreted by primary prostate stromal fibroblasts explanted from aging prostate stroma.
  • Dose-response assays confirmed that, like CXCL5 and CXCL12, CXCL1 and CXCL6 promote low-level proliferative responses from both prostate stromal fibroblasts and epithelial cells.
  • Taken together, these data suggest that inflammatory mediators are secreted by prostatic stroma consequent to aging, that the levels of these mediators are sufficient to promote low-level increases in the proliferative rate of both epithelial and stromal fibroblast cell types.
  • Moreover, these processes may account for the low-level, but cumulative, proliferation of both epithelial and fibroblastic/myofibroblastic cell types that characterizes the aging-associated development of benign prostatic hypertophy.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2004 Oct 1;154(1):36-43 [15381370.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] BJU Int. 1999 Dec;84(9):976-81 [10571623.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1985-92 [10595928.001]
  • [Cites] Urology. 2000 Jun;55(6):892-8 [10840104.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):164-71 [10881026.001]
  • [Cites] Urology. 2000 Nov 1;56(5):828-32 [11068311.001]
  • [Cites] J Leukoc Biol. 2001 Apr;69(4):513-21 [11310836.001]
  • [Cites] J Clin Epidemiol. 2001 Sep;54(9):935-44 [11520654.001]
  • [Cites] Urology. 2001 Dec;58(6 Suppl 1):5-16; discussion 16 [11750242.001]
  • [Cites] J Urol. 2002 May;167(5):2267-70 [11956490.001]
  • [Cites] Scand J Urol Nephrol Suppl. 1988;107:26-31 [2453919.001]
  • [Cites] Lab Invest. 1992 Jan;66(1):96-107 [1370561.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] Eur Urol. 1996;29(3):345-54 [8740022.001]
  • [Cites] J Urol. 2004 Dec;172(6 Pt 1):2421-5 [15538284.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784.001]
  • [Cites] Aging Cell. 2005 Dec;4(6):291-8 [16300481.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Feb;45(2):136-46 [16235240.001]
  • [Cites] J Biol Chem. 2007 Sep 14;282(37):26767-74 [17631494.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):244-54 [18320069.001]
  • [Cites] Prostate. 2002 Jun 1;52(1):43-58 [11992619.001]
  • [Cites] Eur Urol. 2002 Oct;42(4):323-8 [12361895.001]
  • [Cites] Front Biosci. 1997 Jan 1;2:d12-26 [9159205.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2231-5 [15294933.001]
  • (PMID = 18572414.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK065313-010001; United States / NIDDK NIH HHS / DK / R01 DK081841; United States / NCI NIH HHS / CA / P30 CA046592; United States / NIDDK NIH HHS / DK / P50 DK065313; United States / NIDDK NIH HHS / DK / P50 DK065313-010001; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / P30 CA046592-159017; United States / NIDDK NIH HHS / DK / 1 P50 DK065313; United States / NCI NIH HHS / CA / CA046592-159017; United States / NIDDK NIH HHS / DK / R01 DK081841-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS66226; NLM/ PMC2538565
  •  go-up   go-down


38. Vikram A, Jena GB, Ramarao P: Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate; 2010 Jan 1;70(1):79-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia.
  • BACKGROUND: Obesity, dyslipidemia, Hyperinsulinemia, and insulin resistance (IR) are key features of metabolic syndrome and are considered as risk factors for benign prostatic hyperplasia (BPH) as well as type 2 diabetes.
  • Effect of HFD feeding on the testosterone-induced prostatic growth was evaluated.
  • Pioglitazone (PG, 20 mg/kg) was used for the reversal of compensatory hyperinsulinemia and to examine the subsequent effect on the prostatic growth.
  • RESULTS: Prostatic enlargement was observed in the HFD-fed rats.
  • Significant increase in the cell proliferation markers confirmed the occurrence of cellular hyperplasia in the prostate of hyperinsulinemic rat.
  • Enhanced alpha-adrenoceptor mediated contraction in the prostate of HFD-fed rats indicates augmented contractility of the gland.
  • However, testosterone treatment further augmented the prostatic growth in HFD-fed rats.
  • PG treatment led to improved insulin sensitivity, decreased plasma insulin level and prostate weight, indicating the role of compensatory hyperinsulinemia in the prostate growth.
  • CONCLUSIONS: The present investigation reports that HFD-feeding induced hyperinsulinemic condition leads to increased cellular proliferation, enhanced alpha-adrenoceptor mediated contraction, and enlargement of the prostate in rats.
  • [MeSH-major] Cell Proliferation. Hyperinsulinism / complications. Hyperinsulinism / pathology. Insulin Resistance. Prostate / pathology. Prostatic Hyperplasia / etiology. Prostatic Hyperplasia / pathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19790233.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats
  •  go-up   go-down


39. Yazici S, Inci K, Yuksel S, Bilen CY, Ozen H: Radical prostatectomy after previous prostate surgery: effects on surgical difficulty and pathologic outcomes. Urology; 2009 Apr;73(4):856-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical prostatectomy after previous prostate surgery: effects on surgical difficulty and pathologic outcomes.
  • OBJECTIVES: To evaluate the surgical difficulty and pathologic outcomes of patients who had undergone radical prostatectomy after previous prostate surgery.
  • METHODS: A total of 45 patients with previous prostate surgery underwent radical retropubic prostatectomy for prostate cancer.
  • The surgical difficulty and pathologic outcomes for this group of patients (group 1) were compared with those for 50 consecutive patients who had undergone radical retropubic prostatectomy as their only prostatic surgery (group 2).
  • RESULTS: Radical prostatectomy was technically more challenging in the patients after previous prostate surgery compared with surgery-naive patients, with significantly more estimated blood loss (P <.05) and a longer operative time (P <.001).
  • CONCLUSIONS: Although radical retropubic prostatectomy is technically more difficult after previous prostate surgery, it can be performed safely with no difference in pathologic outcomes from those seen in patients with no history of prostate surgery.
  • [MeSH-major] Prostate / surgery. Prostatectomy. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022487.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI: Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol; 2008 Mar;32(3):461-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
  • Aberrant diffuse expression of p63 in prostate carcinoma cells is a rare and poorly understood phenomenon.
  • We studied 19 cases of prostate cancer with aberrant diffuse expression of p63 on needle biopsy and reviewed the subsequent radical prostatectomies in 6 cases.
  • In 19/21 cases, 100% of the cancer nuclei stained intensely for p63, with 70% staining in the remaining 2 cases.
  • In all 8 radical prostatectomies p63 positive cancer was present, with in 2/8 cases both p63 positive cancer and usual p63 negative acinar prostate cancer.
  • The presence of p63 positive atypical glands with an infiltrative pattern and perineural invasion on radical prostatectomy confirmed the needle biopsy diagnosis of carcinoma.
  • Rarely, prostate cancer can aberrantly express diffuse p63 staining in a nonbasal cell distribution leading to the erroneous diagnosis of atrophy or atypical basal cell proliferation.
  • The diagnosis of prostate cancer is based on the morphology and confirmed by the absence of high molecular weight cytokeratin staining and positivity for alpha-methylacyl-CoA racemase in the atypical glands.
  • Pathologists need to be aware of this rare and unusual phenomenon, which is a potential pitfall in prostate cancer diagnosis.
  • [MeSH-major] Adenocarcinoma / chemistry. Biopsy, Needle. Membrane Proteins / analysis. Prostatectomy. Prostatic Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300803.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


41. Cooper CS, Foster CS: Concepts of epigenetics in prostate cancer development. Br J Cancer; 2009 Jan 27;100(2):240-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concepts of epigenetics in prostate cancer development.
  • Substantial evidence now supports the view that epigenetic changes have a role in the development of human prostate cancer.
  • Examination of cancer methylation patterns supports a stem cell origin of prostate cancer.
  • It is well established that methylation of GSTpi is a marker of prostate cancer, and global patterns of histone marking appear to be linked to cancer prognosis with levels of acetylated histones H3K9, H3K18, and H4K12, and of dimethylated H4R3 and H3K4, dividing low-grade prostate cancer (Gleason 6 or less) into two prognostically separate groups.
  • [MeSH-major] Epigenesis, Genetic. Prostatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Cell Res. 2007 Mar;17(3):195-211 [17325692.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4590-5 [17237810.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12422-7 [17640892.001]
  • [Cites] Nature. 2007 Aug 30;448(7157):1063-7 [17728759.001]
  • [Cites] Oncogene. 2007 Oct 4;26(45):6560-5 [17486081.001]
  • [Cites] Development. 2007 Nov;134(22):3959-65 [17928417.001]
  • [Cites] Curr Top Microbiol Immunol. 2008;320:211-24 [18268846.001]
  • [Cites] Methods Mol Biol. 2008;387:95-108 [18287625.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):286-98 [18371363.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):741-50 [18488029.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):904-8 [18568024.001]
  • [Cites] Lancet. 2003 May 17;361(9370):1693-9 [12767735.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):923-33 [12937133.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 20;321(2):455-61 [15358197.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] Clin Cancer Res. 1995 Dec;1(12):1471-8 [9815946.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):391-400 [15765097.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22437-44 [15817459.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1262-6 [15988529.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10604-9 [16009939.001]
  • [Cites] Eur J Hum Genet. 2006 Feb;14(2):159-66 [16391557.001]
  • [Cites] Nucleic Acids Res. 2006;34(2):528-42 [16428248.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):661-71 [16495925.001]
  • [Cites] PLoS Genet. 2006 Mar;2(3):e40 [16596166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10684-9 [16815976.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10242-6 [17079440.001]
  • (PMID = 19002169.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501019
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC2634711
  •  go-up   go-down


42. Dos Reis ST, Pontes J Jr, Villanova FE, Borra PM, Antunes AA, Dall'oglio MF, Srougi M, Leite KR: Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. J Urol; 2009 May;181(5):2320-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
  • PURPOSE: Prostate cancer is the most common tumor in males in Brazil.
  • We investigated the correlation between MMP1, 2, 7 and 9 polymorphisms with susceptibility to prostate cancer, and classic prognostic parameters of prostate cancer.
  • RESULTS: For the MMP1 gene the polymorphic allele was more common in the control group than in the prostate cancer group (p <0.001).
  • For the MMP9 gene the incidence of the polymorphic homozygote genotype was higher in the prostate cancer group (p <0.001).
  • CONCLUSIONS: MMP1 and MMP2 may protect against prostate cancer development and MMP9 may be related to higher risk.
  • [MeSH-major] Genetic Predisposition to Disease / epidemiology. Matrix Metalloproteinases / genetics. Polymorphism, Genetic. Prostatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2010 Mar;183(3):1258 [20097381.001]
  • [ErratumIn] J Urol. 2009 Jul;182(1):400
  • (PMID = 19303106.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


43. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD, Sun Z: A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res; 2007;35(8):2767-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells.
  • Although the vital role of the androgen receptor (AR) has been well demonstrated in primary prostate cancers, its role in the androgen-insensitive prostate cancers still remains unclear.
  • Here, we used a small hairpin RNA approach to directly assess AR activity in prostate cancer cells.
  • Reduction of AR expression in the two androgen-sensitive prostate cancer cell lines, LNCaP and LAPC4, significantly decreased AR-mediated transcription and cell growth.
  • Intriguingly, in two androgen-insensitive prostate cell lines, LNCaP-C42B4 and CWR22Rv1, knockdown of AR expression showed a more pronounced effect on AR-induced transcription and cell growth than androgen depletion.
  • Taken together, our results elucidate an important role for the AR in androgen-insensitive prostate cancer cells, and suggest that AR can be used as a therapeutic target for androgen-insensitive prostate cancers.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Res. 2000 Aug;28(4):211-9 [11011957.001]
  • [Cites] Semin Oncol. 1999 Aug;26(4):407-21 [10482183.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35200-8 [10930412.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):152-5 [11125075.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10823-8 [11535819.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11336-44 [11792709.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5515-20 [11960009.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):3001-15 [12089231.001]
  • [Cites] Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9 [12231070.001]
  • [Cites] Mol Endocrinol. 2002 Oct;16(10):2181-7 [12351684.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1363-9 [14501770.001]
  • [Cites] Urology. 2003 Nov;62(5 Suppl 1):21-6 [14607214.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] Mol Biol Cell. 2004 Feb;15(2):506-19 [14617803.001]
  • [Cites] J Gene Med. 2004 Feb;6 Suppl 1:S125-38 [14978756.001]
  • [Cites] Endocrinology. 1988 Feb;122(2):552-62 [2828003.001]
  • [Cites] Cancer Treat Res. 1989;46:177-93 [2577189.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):37-41 [1525065.001]
  • [Cites] Recent Prog Horm Res. 1994;49:249-74 [8146426.001]
  • [Cites] Am J Pathol. 1994 Apr;144(4):735-46 [7512791.001]
  • [Cites] Int J Cancer. 1994 May 1;57(3):406-12 [8169003.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2861-4 [8187068.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1393-8 [7723794.001]
  • [Cites] J Biol Chem. 1996 Mar 15;271(11):6379-88 [8626436.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5517-21 [8643607.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3042-6 [8674060.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):495-9 [9012480.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):1-9 [9422516.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14 [9482916.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):887-94 [9714059.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Nat Med. 1999 Mar;5(3):280-5 [10086382.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Jul-Aug;35(7):403-9 [10462204.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2410-34 [11018010.001]
  • (PMID = 17426117.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA070297-11A2; United States / NCI NIH HHS / CA / R01 CA070297-10; United States / NCI NIH HHS / CA / CA70297; United States / NCI NIH HHS / CA / R01 CA070297; United States / NCI NIH HHS / CA / K01 CA123532; United States / NIDDK NIH HHS / DK / R01 DK061002-05; United States / NCI NIH HHS / CA / CA070297-10; United States / NCI NIH HHS / CA / CA087767-05; United States / NCI NIH HHS / CA / R01 CA070297-11A2; United States / NCI NIH HHS / CA / CA087767-04; United States / NCI NIH HHS / CA / R01 CA070297-12; United States / NIDDK NIH HHS / DK / R01 DK061002-04; United States / NCI NIH HHS / CA / CA070297-12; United States / NCI NIH HHS / CA / R01 CA087767-05; United States / NIDDK NIH HHS / DK / DK061002-04; United States / NCI NIH HHS / CA / R29 CA070297; United States / NIDDK NIH HHS / DK / Z01 DK061002; United States / NCI NIH HHS / CA / CA123532-01; United States / NIDDK NIH HHS / DK / R56 DK061002; United States / NCI NIH HHS / CA / R01 CA087767; United States / NIDDK NIH HHS / DK / R01 DK061002; United States / NIDDK NIH HHS / DK / DK061002-05; United States / NIDDK NIH HHS / DK / DK61002; United States / NCI NIH HHS / CA / R01 CA087767-04; United States / NCI NIH HHS / CA / CA87767
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Receptor Antagonists; 0 / Androgens; 0 / Receptors, Androgen; 08J2K08A3Y / Dihydrotestosterone
  • [Other-IDs] NLM/ PMC1885678
  •  go-up   go-down


44. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ: Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol; 2008 Feb;53(2):244-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
  • OBJECTIVES: Both normal and pathological growth of the prostate is dependent on dihydrotestosterone (DHT) synthesis, which is catalysed by two 5alpha-reductase (5alphaR) isoenzymes, 5alphaR1 and 5alphaR2, of which only 5alphaR2 has traditionally been viewed as important in the prostate.
  • The objective of this study was to evaluate the role of both isoenzymes during development/progression of prostate cancer.
  • METHODS: A thorough literature search was performed with the MEDLINE database to identify studies that have assessed expression of 5alphaR1/2 in prostate tissue.
  • RESULTS: DHT suppression data for the 5alphaR2-specific inhibitor, finasteride, and the dual 5alphaR1/2 inhibitor, dutasteride, show that both isoenzymes are active in benign prostate.
  • Furthermore, immunostaining studies have shown that 5alphaR1 expression increases and 5alphaR2 expression decreases in prostatic intraepithelial neoplasia (PIN) and prostate cancer, compared with nonmalignant prostate tissue.
  • Both isoenzymes appear increased in high-grade compared with low-grade localised cancer.
  • Dual inhibition of both isoenzymes with dutasteride may, therefore, be effective in preventing or delaying the growth of prostate cancer.
  • The 4-yr REduction by DUtasteride of prostate Cancer Events (REDUCE) trial is underway to test this hypothesis.
  • Androgen-withdrawal therapy can reverse prostate tumour growth by reducing circulating testosterone.
  • However, 5alphaR-catalysed DHT synthesis within the prostate can continue and most tumours eventually develop resistance to androgen-deprivation therapy.
  • CONCLUSIONS: The consensus of evidence to date shows that 5alphaR1 is present in the prostate, and that levels are higher in malignant compared with benign prostate hyperplasia tissue.
  • [MeSH-major] 3-Oxo-5-alpha-Steroid 4-Dehydrogenase / metabolism. Prostatic Neoplasms / enzymology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006217.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Azasteroids; 0 / Enzyme Inhibitors; 0 / Isoenzymes; 57GNO57U7G / Finasteride; EC 1.3.99.5 / 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; O0J6XJN02I / Dutasteride
  • [Number-of-references] 59
  •  go-up   go-down


45. Benchikh El Fegoun A, Villers A, Moreau JL, Richaud P, Rebillard X, Beuzeboc P: [PSA and follow-up after treatment of prostate cancer]. Prog Urol; 2008 Mar;18(3):137-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [PSA and follow-up after treatment of prostate cancer].
  • [Transliterated title] PSA et suivi après traitement du cancer de la prostate.
  • In the absence of residual cancer, PSA becomes undetectable by the first month after total prostatectomy: less than 0.1 ng/ml (or less than 0.07 ng/ml) for the ultrasensitive assay method and less than 0.2 ng/ml for the other methods.
  • In the presence of residual cancer, PSA either does not become undetectable or increases after an initial undetectable period.
  • No consensus has been reached concerning the indication for complementary investigations by bone scan and abdominopelvic CT in patients with biochemical recurrence after treatment of localized cancer without endocrine therapy.
  • [MeSH-major] Continuity of Patient Care. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Humans. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / diagnosis. Prostatectomy. Radiotherapy, Adjuvant


46. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F: Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol; 2009 Jun;55(6):1321-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insignificant prostate cancer and active surveillance: from definition to clinical implications.
  • CONTEXT: Due to early detection strategies, prostate cancer is diagnosed early in its natural history.
  • It remains unclear whether all patients diagnosed with prostate cancer warrant radical treatment or may benefit from delayed intervention following active surveillance.
  • EVIDENCE ACQUISITION: Medline was searched using the following terms: prostate cancer, active surveillance and expectant management for dates up to October 2008.
  • Once a patients requires active treatment, most patients still present with curable prostate cancer.
  • Furthermore, only few deaths due to prostate cancer have occurred.
  • CONCLUSIONS: Active surveillance is an alternative option to immediate treatment of men with presumed insignificant prostate cancer.
  • It seems that criteria used to identify men with low-risk prostate cancer are rather similar, and immediate treatment of men meeting these criteria may result in an unnecessary number of treatments in these highly selected patients.
  • [MeSH-major] Monitoring, Physiologic / methods. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Disease Progression. Early Detection of Cancer. Evidence-Based Medicine. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Observation / methods. Patient Selection. Risk Assessment. Sensitivity and Specificity. Time Factors


47. Haworth A, Ebert M, St Clair S, Carey BM, Flynn A, Bottomley DM, Duchesne GM, Joseph D, Ash D: Impact of selection of post-implant technique on dosimetry parameters for permanent prostate implants. Brachytherapy; 2005;4(2):146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of selection of post-implant technique on dosimetry parameters for permanent prostate implants.
  • PURPOSE: To investigate the variability of prostate implant quality indices between three different methods of calculating the post-implant dose distribution.
  • METHODS AND MATERIALS: In a study of 9 permanent prostate implant patients, post-implant dosimetry was carried out using three methods of identifying seed positions within the prostate volume:.
  • (1) prostate volumes defined by transrectal ultrasound (TRUS) immediately following implant were registered with shift-film defined seed positions, (2) seeds were identified directly from the post-implant TRUS images, and (3) CT was used to define seed positions and prostate volumes from images acquired at 41-65 days post-implant.
  • For each method, the volume of prostate receiving 90%, 100%, and 150% of the prescribed dose (V90, V100, V150) and the dose delivered to 90% of the prostate volume (D90) were calculated.
  • CONCLUSIONS: There are many uncertainties in the calculation of parameters that are commonly used to describe the quality of a permanent prostate implant.
  • Differences in the parameters calculated were most likely a result of a combination of factors including uncertainties in delineating the prostate with different imaging modalities, differences in source identification techniques, and intraobserver variability.
  • [MeSH-major] Brachytherapy / instrumentation. Prostatic Neoplasms / radiotherapy. Prostheses and Implants

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893269.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr: Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst; 2006 Apr 19;98(8):529-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.
  • BACKGROUND: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States.
  • Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed.
  • We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer.
  • METHODS: We included 5519 men from the placebo group of the PCPT who underwent prostate biopsy, had at least one PSA measurement and a digital rectal examination (DRE) performed during the year before the biopsy, and had at least two PSA measurements performed during the 3 years before the prostate biopsy.
  • Logistic regression was used to model the risk of prostate cancer and high-grade disease associated with age at biopsy, race, family history of prostate cancer, PSA level, PSA velocity, DRE result, and previous prostate biopsy.
  • RESULTS: A total of 1211 (21.9%) men were diagnosed with prostate cancer by prostate biopsy.
  • Variables that predicted prostate cancer included higher PSA level, positive family history of prostate cancer, and abnormal DRE result, whereas a previous negative prostate biopsy was associated with reduced risk.
  • Higher PSA level, abnormal DRE result, older age at biopsy, and African American race were predictive for high-grade disease (Gleason score > or =7) whereas a previous negative prostate biopsy reduced this risk.
  • CONCLUSIONS: This predictive model allows an individualized assessment of prostate cancer risk and risk of high-grade disease for men who undergo a prostate biopsy.
  • [MeSH-major] Biopsy, Needle. Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / pathology
  • [MeSH-minor] African Americans / statistics & numerical data. Age Factors. Aged. Confounding Factors (Epidemiology). Digital Rectal Examination. Genetic Predisposition to Disease. Humans. Logistic Models. Male. Predictive Value of Tests. Prognosis. Prostate-Specific Antigen / blood. Randomized Controlled Trials as Topic. Research Design. Risk Assessment. Risk Factors. Time Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Apr 19;98(8):506-7 [16622114.001]
  • (PMID = 16622122.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5UO1CA86402-04; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA37429; United States / NCI NIH HHS / CA / CA45808
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


49. Halpin M, Phillips M, Oliffe JL: Prostate cancer stories in the Canadian print media: representations of illness, disease and masculinities. Sociol Health Illn; 2009 Mar;31(2):155-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer stories in the Canadian print media: representations of illness, disease and masculinities.
  • Despite the popularity of print media as an information source for men with prostate cancer, the representation of prostate cancer within this medium remains relatively understudied.
  • This article details the findings from an analysis of prostate cancer articles published in two Canadian national newspapers, The Globe and Mail and the National Post, from January 2001 through to December 2006.
  • The 817 prostate cancer articles published during this period were retrieved and reviewed using manifest and latent analyses.
  • The latent analysis was guided by the connections between masculinities and prostate cancer in the newspapers' stories.
  • Findings indicated a low frequency of articles that substantively discussed prostate cancer and that the descriptive content reproduced hegemonic masculine ideals, such as competition and stoicism.
  • These findings support how representations of prostate cancer in Canadian newspapers predominately replicate detrimental ideologies and perspectives of men's health.
  • [MeSH-major] Gender Identity. Health Knowledge, Attitudes, Practice. Men's Health. Newspapers as Topic / statistics & numerical data. Prostatic Neoplasms. Social Perception

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Men's Health.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983423.001).
  • [ISSN] 1467-9566
  • [Journal-full-title] Sociology of health & illness
  • [ISO-abbreviation] Sociol Health Illn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


50. Casciani E, Gualdi GF: Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom Imaging; 2006 Jul-Aug;31(4):490-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging.
  • The results of recent studies of magnetic resonance imaging (MRI) combined with three-dimensional magnetic resonance spectroscopic imaging (3D-MRSI) demonstrate that the MRI/3D-MRSI exam is a unique method by which to noninvasively study the cellular metabolism and anatomy of the prostate.
  • 3D-MRSI is emerging as the most specificity tool for non-invasive evaluation of the prostate cancer.
  • The results of current MRI/3D-MRSI studies also provide evidence that the magnitude of metabolic changes in regions of cancer before therapy, as well as the extent of the time course of metabolic changes after therapy, may improve our understanding of cancer aggressiveness.
  • Assessment of cancer spread outside the prostate can be significantly improved by combining MRI findings with estimates of metabolic abnormalities provided by 3D-MRSI.
  • Clinically, combined MRI/3D-MRSI has already demonstrated a potential for improved diagnosis, staging, and treatment planning for patients with prostate cancer.
  • This article reviewed the value of 3D-MRS imaging for the diagnosis, localization, staging, aggressiveness, and treatment planning of prostate cancer.
  • [MeSH-major] Imaging, Three-Dimensional. Magnetic Resonance Spectroscopy. Prostatic Neoplasms / diagnosis. Prostatitis / diagnosis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955379.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


51. Gallus S, Foschi R, Negri E, Talamini R, Franceschi S, Montella M, Ramazzotti V, Tavani A, Dal Maso L, La Vecchia C: Dietary zinc and prostate cancer risk: a case-control study from Italy. Eur Urol; 2007 Oct;52(4):1052-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary zinc and prostate cancer risk: a case-control study from Italy.
  • OBJECTIVES: Zinc concentration is higher in the prostate than in most other tissues.
  • Since information on the role of zinc on prostate carcinogenesis is controversial, we analysed the issue in a case-control study.
  • METHODS: Between 1991 and 2002, we conducted a multicentre hospital-based case-control study on prostate cancer in Italy.
  • Cases included 1294 men with incident, histologically confirmed prostate cancer.
  • The trend in risk was significant for advanced cancers only, the OR being 2.02 (95% CI, 1.14-3.59) for prostate cancers with a high Gleason score.
  • CONCLUSIONS: In this large study we found a direct association between high zinc intake and prostate cancer risk, particularly for advanced cancers.
  • Our findings allow one to exclude a favourable effect of zinc on prostate carcinogenesis.
  • [MeSH-major] Diet. Prostatic Neoplasms / epidemiology. Zinc / adverse effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Oct;52(4):1056-7 [17292534.001]
  • [CommentIn] Eur Urol. 2007 Oct;52(4):1262-3; author reply 1263-4 [17445972.001]
  • (PMID = 17292532.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] J41CSQ7QDS / Zinc
  •  go-up   go-down


52. Gunes S, Bagci H, Sarikaya S, Bilen CY, Kara N: Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia. DNA Cell Biol; 2007 Dec;26(12):873-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
  • We investigated the association of prostate cancer (PCa) and benign prostatic hyperplasia (BPH) with genetic polymorphisms in prostate-specific antigen (PSA) (-158 G/A) and 17-hydroxylase (CYP17) (-34 T/C) genes in a Turkish population.
  • [MeSH-major] Polymorphism, Genetic. Prostate-Specific Antigen / genetics. Prostatic Hyperplasia / genetics. Prostatic Neoplasms / genetics. Steroid 17-alpha-Hydroxylase / genetics


53. Ma S, Guan XY, Beh PS, Wong KY, Chan YP, Yuen HF, Vielkind J, Chan KW: The significance of LMO2 expression in the progression of prostate cancer. J Pathol; 2007 Feb;211(3):278-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of LMO2 expression in the progression of prostate cancer.
  • This study has investigated LMO2 expression in human prostatic tissue specimens, prostate cancer cell lines, and xenografts; and has assessed the possible role and mechanism of LMO2 in prostate carcinogenesis.
  • Immunohistochemical analysis on a tissue microarray consisting of 91 human prostate specimens, including normal, prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia, and invasive carcinoma, revealed that overexpression of LMO2 was significantly associated with advanced tumour stage, as measured by Gleason score (p = 0.012), as well as with the development of distant metastasis (p = 0.018).
  • These data were supported by quantitative real-time PCR experiments, where LMO2 mRNA levels were found to be significantly higher in prostate tumour specimen than in normal epithelium (p = 0.037).
  • The expression of LMO2 in cell lines and xenografts representing androgen-dependent (AD) and androgen-independent (AI) prostate cancer stages was further studied.
  • Taken together, these findings provide the first evidence to support the hypothesis that LMO2 may play an important role in prostate cancer progression, possibly via repression of E-cadherin expression.
  • [MeSH-major] Adenocarcinoma / pathology. DNA-Binding Proteins / genetics. Gene Expression Regulation, Neoplastic. Metalloproteins / genetics. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 17167821.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger
  •  go-up   go-down


54. Meyer P, Zuern C, Hermanns N, Haak T: The association between paternal prostate cancer and type 2 diabetes. J Carcinog; 2007;6:14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between paternal prostate cancer and type 2 diabetes.
  • However, diabetes mellitus may be a protective factor for prostate cancer since both were found to be negatively associated.
  • RESULTS: Concerning the 794 type 2 diabetic patients and 775 controls, we observed that cancer of cervix uteri was elevated among mothers of controls (odds ratio (OR) 0.19; 95% confidence interval (CI) 0.02 to 0.88; p = 0.033).
  • Most notably, a lower number of prostate cancers was observed in fathers of diabetic patients (OR 0.47; 95% CI 0.22 to 0.94; p = 0.032).
  • Since diabetic patients were 14.3 years older than the controls, higher levels of cancer history among parents of diabetic patients would have been expected.
  • Thus, the observed lower level of history of prostate cancer can be regarded as highly reliable.The analysis of 801 type 2 diabetics and 1267 controls showed that cancer of stomach was elevated among mothers of controls (OR 2.67; p = 0.0106).
  • In accordance with the previous investigation, we again obseved a lower number of prostate cancers in fathers of diabetic patients (OR 0.49; p = 0.0279).However, the application of the statistical method of Mantel-Haenszel showed no significant result concerning any of the cancer histories.
  • CONCLUSION: Fathers of patients suffering from type 2 diabetes were diagnosed less frequently with prostate cancer compared to fathers of non-diabetic controls.
  • As first-degree relatives, e.g. diabetic patients and their fathers, share 50% of their genes, it appears plausible that genetic factors may play an important role in the negative association between diabetes and prostate cancer.
  • However, different statistic analyses showed controversial results concerning the effect of type 2 diabetes on prostate cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1360-5 [9308706.001]
  • [Cites] Cancer Invest. 2002;20(2):157-65 [11901534.001]
  • [Cites] Cancer Causes Control. 1998 Jan;9(1):3-9 [9486458.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):39-66 [10963619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5 [10984506.001]
  • [Cites] Proc Nutr Soc. 2001 Feb;60(1):91-106 [11310428.001]
  • [Cites] Epidemiol Rev. 2001;23(1):59-66 [11588855.001]
  • [Cites] Eur J Cancer Prev. 2002 Apr;11(2):125-8 [11984129.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):258-61 [12397646.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):807-11 [8634649.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 21;87(12):930-1 [7666483.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):950-3 [7947103.001]
  • [Cites] J Natl Cancer Inst. 1996 Oct 16;88(20):1472-7 [8841022.001]
  • [Cites] Cancer Causes Control. 1991 Sep;2(5):307-14 [1932543.001]
  • [Cites] JAMA. 1995 May 24-31;273(20):1605-9 [7745774.001]
  • [Cites] Am J Epidemiol. 1996 May 15;143(10):1002-6 [8629606.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):360-3 [9139868.001]
  • [Cites] Br J Cancer. 1997;76(9):1115-8 [9365156.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):542-7 [10088625.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):2014-9 [10843190.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):76-80 [10973253.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):421-7 [11352850.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • (PMID = 17897447.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2042980
  •  go-up   go-down


55. Kuo YF, Goodwin JS, Shahinian VB: Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer. BMC Health Serv Res; 2008 Jul 14;8:146
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer.
  • BACKGROUND: Use of gonadotropin-releasing hormone (GnRH) agonists has become popular for virtually all stages of prostate cancer.
  • We hypothesized that some men receive these agents after only a limited work-up for their cancer.
  • METHODS: We used linked Surveillance, Epidemiology and End-Results (SEER)-Medicare data from 1993 through 2001 to identify GnRH agonist use in men with either a diagnosis of prostate cancer registered in SEER, or with a diagnosis of prostate cancer based only on Medicare claims (from the 5% control sample of Medicare beneficiaries residing in SEER areas without a registered diagnosis of cancer).
  • The proportion of incident GnRH agonist users without a registry diagnosis of prostate cancer was calculated.
  • Factors associated with lack of a registry diagnosis were examined in multivariable analyses.
  • RESULTS: Of incident GnRH agonist users, 8.9% had no diagnosis of prostate cancer registered in SEER.
  • In a multivariable logistic regression model, lack of a registry diagnosis of prostate cancer in GnRH agonist users was significantly more likely with increasing comorbidity, whereas it was less likely in men who had undergone either inpatient admission or procedures such as radical prostatectomy, prostate biopsy, or transurethral resection of the prostate.
  • CONCLUSION: Reliance solely on tumor registry data may underestimate the rate of GnRH agonist use in men with prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24 [17925537.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1537-45 [12381706.001]
  • [Cites] Urology. 2003 Feb;61(2 Suppl 1):32-8 [12667885.001]
  • [Cites] N Engl J Med. 1999 Dec 9;341(24):1781-8 [10588962.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):103-6 [12126818.001]
  • [Cites] Urology. 2002 Aug;60(2):201-8 [12137810.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):981-9 [12837834.001]
  • [Cites] Am J Epidemiol. 1983 Dec;118(6):852-6 [6650486.001]
  • [Cites] J Am Geriatr Soc. 1986 Jan;34(1):20-6 [3941240.001]
  • [Cites] JAMA. 1987 Dec 4;258(21):3125-30 [3669259.001]
  • [Cites] Ann Intern Med. 1996 Mar 15;124(6):577-84 [8597322.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2343-50 [8635041.001]
  • [Cites] JAMA. 1998 Sep 16;280(11):975-80 [9749479.001]
  • [Cites] Med Care. 2004 Nov;42(11):1111-6 [15586838.001]
  • [Cites] N Engl J Med. 2005 Jan 13;352(2):154-64 [15647578.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 [15817329.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1615-24 [15742331.001]
  • [Cites] Med Care. 2005 Jul;43(7):705-12 [15970786.001]
  • [Cites] JAMA. 2005 Jul 13;294(2):238-44 [16014598.001]
  • [Cites] Arch Intern Med. 2006 Feb 27;166(4):465-71 [16505268.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1708-14 [16544313.001]
  • [Cites] J Urol. 2006 Aug;176(2):526-31 [16813882.001]
  • [Cites] J Gen Intern Med. 2007 Aug;22(8):1139-43 [17554589.001]
  • [Cites] Urology. 2002 Sep;60(3 Suppl 1):7-11; discussion 11-2 [12231037.001]
  • (PMID = 18620606.001).
  • [ISSN] 1472-6963
  • [Journal-full-title] BMC health services research
  • [ISO-abbreviation] BMC Health Serv Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116758-03; United States / NCI NIH HHS / CA / CA116758-04; United States / NCI NIH HHS / CA / CA116758-01; United States / NCI NIH HHS / CA / R01CA116758; United States / NCI NIH HHS / CA / R01 CA116758-04; United States / NCI NIH HHS / CA / R01 CA116758-01; United States / NCI NIH HHS / CA / R01 CA116758; United States / NCI NIH HHS / CA / CA116758-02; United States / NCI NIH HHS / CA / R01 CA116758-02; United States / NCI NIH HHS / CA / P50CA105631; United States / NCI NIH HHS / CA / P50 CA105631; United States / NCI NIH HHS / CA / CA116758-03
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Other-IDs] NLM/ PMC2483971
  •  go-up   go-down


56. Gitenay D, Baron VT: Is EGR1 a potential target for prostate cancer therapy? Future Oncol; 2009 Sep;5(7):993-1003
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is EGR1 a potential target for prostate cancer therapy?
  • Prostate cancer is a major cause of cancer-related death in American men, for which finding new therapeutic strategies remains a challenge.
  • Although it has long been considered a tumor suppressor, a wealth of new evidence shows that EGR1 promotes the progression of prostate cancer.
  • While EGR1 mediates apoptosis in response to stress and DNA damage by regulating a tumor suppressor network, it also promotes the proliferation of prostate cancer cells by a mechanism that is not fully understood.
  • Thus, EGR1 might be targeted for prostate cancer therapy either by ectopic expression in combination with radiotherapy or chemotherapy, or by direct inhibition for systemic treatment.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1994 Aug 1;8(15):1803-16 [7958858.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] J Biol Chem. 1995 Apr 28;270(17):9971-7 [7730380.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;50:191-224 [7754034.001]
  • [Cites] Curr Biol. 1995 Jul 1;5(7):747-57 [7583121.001]
  • [Cites] J Urol. 1996 Mar;155(3):975-81 [8583621.001]
  • [Cites] J Cell Biol. 1996 Apr;133(1):211-20 [8601609.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3545-53 [8668170.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):12903-8 [8662677.001]
  • [Cites] Mol Cell Biol. 1996 Aug;16(8):4566-72 [8754857.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11831-6 [8876223.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):30222-6 [8939974.001]
  • [Cites] Crit Rev Oncog. 1996;7(1-2):101-25 [9109500.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):20131-8 [9242687.001]
  • [Cites] Neurochem Int. 1997 Oct;31(4):477-510; discussion 517-6 [9307998.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33056-61 [9407088.001]
  • [Cites] Mol Endocrinol. 1998 Jan;12(1):107-22 [9440815.001]
  • [Cites] Cancer Gene Ther. 1998 Jan-Feb;5(1):3-28 [9476963.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50 [9560261.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2461-8 [9622090.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2720-3 [9661880.001]
  • [Cites] Oncogene. 1998 Jun 4;16(22):2915-26 [9671412.001]
  • [Cites] J Biol Chem. 1998 Nov 20;273(47):31327-36 [9813041.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15382-7 [9860977.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):665-70 [10079243.001]
  • [Cites] Trends Neurosci. 1999 Apr;22(4):167-73 [10203854.001]
  • [Cites] J Biol Chem. 1999 Jul 9;274(28):19559-64 [10391889.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4291-6 [10485474.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1276-312 [18483217.001]
  • [Cites] J Biol Chem. 2008 Oct 24;283(43):29215-27 [18718911.001]
  • [Cites] Genome Biol. 2008;9(11):R166 [19032775.001]
  • [Cites] EMBO J. 2009 Jan 7;28(1):21-33 [19057511.001]
  • [Cites] Mol Carcinog. 2009 Jan;48(1):38-44 [18506761.001]
  • [Cites] Oncogene. 2009 Feb 26;28(8):1121-31 [19137013.001]
  • [Cites] J Neurochem. 2004 Dec;91(5):1199-210 [15569263.001]
  • [Cites] FASEB J. 2005 Jan;19(1):62-72 [15629896.001]
  • [Cites] EMBO J. 2005 Jan 12;24(1):128-37 [15616591.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1028-36 [15709168.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5133-43 [15958557.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Nov;315(2):788-95 [16081677.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9934-42 [16267018.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):349-50 [16286241.001]
  • [Cites] Cancer Gene Ther. 2006 Jan 1;13(1):1-6 [16082378.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1059:33-40 [16382041.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:206-17 [16387689.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):278-87 [16170359.001]
  • [Cites] Cancer Gene Ther. 2006 Feb;13(2):115-24 [16138117.001]
  • [Cites] J Cell Biochem. 2006 Apr 15;97(6):1292-9 [16552752.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6708-13 [16818645.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4142-6 [16857784.001]
  • [Cites] J Invest Dermatol. 2007 Feb;127(2):400-10 [16960555.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell Death Differ. 2007 Mar;14(3):436-46 [16990849.001]
  • [Cites] Adv Exp Med Biol. 2007;595:127-48 [17569208.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5262-70 [17875754.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9835-43 [17942914.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6247-51 [17975134.001]
  • [Cites] Cancer Gene Ther. 2008 Mar;15(3):133-9 [18157146.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1369-77 [18316600.001]
  • [Cites] Oncogene. 2000 Feb 10;19(6):791-800 [10698497.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9749-57 [10734128.001]
  • [Cites] DNA Seq. 2000;10(6):429-32 [10826704.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] J Biol Chem. 2000 Dec 8;275(49):38524-31 [10984481.001]
  • [Cites] Nat Med. 2001 Jan;7(1):101-7 [11135623.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 4;283(2):480-6 [11327726.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3279-86 [11035041.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):935-9 [11567222.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11563-8 [11553783.001]
  • [Cites] Am J Clin Oncol. 2001 Oct;24(5):500-5 [11586104.001]
  • [Cites] Nat Cell Biol. 2001 Dec;3(12):1124-8 [11781575.001]
  • [Cites] Tumour Biol. 2002 Mar-Apr;23(2):93-102 [12065847.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):173-93 [12085961.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 21;1592(2):163-7 [12379479.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3233-8 [12629205.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):11802-10 [12556466.001]
  • [Cites] Life Sci. 2003 May 16;72(26):2975-92 [12706485.001]
  • [Cites] Oncogene. 2003 Jul 3;22(27):4194-204 [12833142.001]
  • [Cites] Can J Urol. 2003 Aug;10(4):1924-33 [14503938.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3016-24 [12855573.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39906-11 [12890669.001]
  • [Cites] Mol Cancer Ther. 2004 Jan;3(1):11-20 [14749471.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1002:197-216 [14751836.001]
  • [Cites] Mol Cell. 2004 Jul 2;15(1):83-94 [15225550.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] Science. 1987 Nov 6;238(4828):797-9 [3672127.001]
  • [Cites] Cell. 1988 Apr 8;53(1):37-43 [3127059.001]
  • [Cites] Oncogene. 1987;1(3):263-70 [3330774.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jul;85(13):4691-5 [3133658.001]
  • [Cites] Nucleic Acids Res. 1988 Sep 26;16(18):8835-46 [3140220.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(21):7857-61 [3141919.001]
  • [Cites] Mol Cell Biol. 1989 Nov;9(11):4889-95 [2513479.001]
  • [Cites] Oncogene. 1991 May;6(5):867-71 [2052361.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4716-20 [1873816.001]
  • [Cites] Mol Cell Biol. 1993 Aug;13(8):4556-71 [8336701.001]
  • [Cites] J Biol Chem. 1993 Aug 15;268(23):16949-57 [8349585.001]
  • [Cites] Mol Cell Biol. 1993 Nov;13(11):6858-65 [8413279.001]
  • (PMID = 19792968.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102688-05; United States / NCI NIH HHS / CA / R01 CA102688; United States / NCI NIH HHS / CA / R01 CA102688-05; United States / NCI NIH HHS / CA / R01-CA102688
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Early Growth Response Protein 1
  • [Number-of-references] 98
  • [Other-IDs] NLM/ NIHMS155263; NLM/ PMC2776080
  •  go-up   go-down


57. Briganti A, Chun FK, Suardi N, Gallina A, Walz J, Graefen M, Shariat S, Ebersdobler A, Rigatti P, Perrotte P, Saad F, Montorsi F, Huland H, Karakiewicz PI: Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer; 2007 Dec;43(18):2669-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate volume and adverse prostate cancer features: fact not artifact.
  • PURPOSE: A recent prostate cancer finasteride chemoprevention trial showed a higher rate of sextant biopsy-detected high grade prostate cancer (HGPCa) in finasteride exposed men, whose prostates were significantly smaller than those of controls.
  • We investigated the association between prostate size and prostate cancer grade and stage in a large (n=3412) single center radical prostatectomy cohort, which was unexposed to any form of hormonal manipulation.
  • CONCLUSIONS: Our findings demonstrate that prostate cancers located in small glands are fundamentally more aggressive than those located within larger glands.
  • In consequence, prostate cancer detection and treatment strategies should account for prostate volume.
  • [MeSH-major] Prostate / pathology. Prostatectomy / statistics & numerical data. Prostatic Neoplasms / pathology


58. Zhang P, Wang ZM, Chong T, Zhao LH: [Analysis of reference range responsible to normal percent value of free prostate specific antigen from men without prostate disease]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep;38(5):871-3, 903
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of reference range responsible to normal percent value of free prostate specific antigen from men without prostate disease].
  • OBJECTIVE: To study the effect of age on the percent value for free prostate specific antigen (fPSA) from men, and the relationships between the percent fPSA and the pathological grade or the clinical stage of prostate cancer (PCa), and also to determine appropriate reference value range for Chinese men.
  • Out of 713, 679 men without prostate disease were divided into 5 groups by age, and then the relationships were studied between man age and PSA, fPSA or percent fPSA, respectively.
  • The relationships between pathological grade or clinical stage and percent fPSA were also studied in the rest 34 participants suffering from PCa.
  • With the help of the related data of men without prostate disease, the appropriate reference value range was established for Chinese men.
  • The percent fPSA was also correlated with pathological grade, clinical stage of Pca (r was 0.427 and -0.332 respectively, P < 0.05).
  • According to the data of our early studies and the reference value range of percent fPSA given by the test kit and the previously reported medical references, the data of 10%, 15% and 20% were selected as the percent fPSA threshold values to distinguish PCa or health men without prostate disease.
  • CONCLUSION: The percent fPSA may be more useful than PSA in the detection of prostate cancer.
  • With the percent fPSA dropping down, the pathological differentiating grade of PCa appears lower, but the clinical stage is high, the malignant degree is also increased.
  • The reference range of > or = 15% percent fPSA is more appropriate threshold value for diagnosing the prostate cancer in Chinese man population.
  • [MeSH-major] Prostate-Specific Antigen / blood
  • [MeSH-minor] Adult. Age Factors. Aged. Biomarkers, Tumor / blood. Humans. Male. Middle Aged. Neoplasm Staging. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology. Reference Values. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17953381.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


59. Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T, Babaian RJ: Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol; 2008 Jun;179(6):2187-91; discussion 2191
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
  • PURPOSE: We evaluated the hypothesis that circulating tumor cells as determined using the CellSearch System would correlate with tumor volume, pathological stage and Gleason score in men with localized prostate cancer.
  • MATERIALS AND METHODS: Samples of blood (30 ml) were drawn from 97 men with localized prostate cancer before radical prostatectomy, on postoperative days 2 to 3 and at 6 weeks.
  • A control group consisted of 25 men with an increased prostate specific antigen and no tumor detected on extended prostate biopsy.
  • RESULTS: Circulating tumor cells were detected in 21% of patients with cancer and 20% of controls (p = 0.946).
  • Of the 20 patients with cancer who had circulating tumor cells at baseline 18 showed no circulating tumor cells after surgery.
  • Only 3.1% of the men with cancer and 8% of the control group had 3 or more circulating tumor cells per 22.5 ml blood at baseline.
  • CONCLUSIONS: In metastatic breast, prostate and other cancers more than 5 circulating tumor cells are often detected using the CellSearch System, and may correlate with prognosis.
  • However, in the setting of localized prostate cancer the number of detectable circulating tumor cells was low, with findings comparable to those in men who were biopsy negative for cancer.
  • [MeSH-major] Neoplastic Cells, Circulating. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology


60. Toles CA: Black men are dying from prostate cancer. ABNF J; 2008;19(3):92-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Black men are dying from prostate cancer.
  • Prostate cancer is the most frequently diagnosed cancer in the United States, accounting for 33% of all cancer cases among men (American Cancer Society, 2004).
  • In the United States the number of new cases of prostate cancer was estimated at 230,110 and 29,900 will die (American Cancer Society, 2004).
  • Black men (African-American) are 2.5 times more likely to die of prostate cancer than White men (Peters, 2005).
  • [MeSH-major] African Americans / ethnology. African Americans / statistics & numerical data. Prostatic Neoplasms / ethnology. Prostatic Neoplasms / mortality
  • [MeSH-minor] Attitude to Health / ethnology. Cause of Death. Digital Rectal Examination. European Continental Ancestry Group / ethnology. Food Habits / ethnology. Health Education. Health Knowledge, Attitudes, Practice. Health Planning Guidelines. Health Services Needs and Demand. Health Status Disparities. Healthcare Disparities. Humans. Male. Mass Screening. Primary Prevention. Prostate-Specific Antigen. Risk Factors. Social Class. United States / epidemiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18717207.001).
  • [ISSN] 1046-7041
  • [Journal-full-title] The ABNF journal : official journal of the Association of Black Nursing Faculty in Higher Education, Inc
  • [ISO-abbreviation] ABNF J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 32
  •  go-up   go-down


61. Hooker S, Bonilla C, Akereyeni F, Ahaghotu C, Kittles RA: NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans. Prostate Cancer Prostatic Dis; 2008;11(4):349-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans.
  • Prostate cancer is a common malignancy that disproportionately affects African-American men.
  • Fourteen single nucleotide polymorphisms in NAT2 and four NER genes (ERCC1, XPF/ERCC4, XPG/ERCC5 and CSB/ERCC6) were genotyped in a case-control study of 254 African-American prostate cancer cases and 301 healthy controls from Washington, DC.
  • We found that individuals homozygous for the XPG/ERCC5 -72C/T promoter polymorphism had a significant reduction in risk, for prostate cancer (OR=0.12; 95% CI=0.03-0.48).
  • The protective effect of the promoter SNP on risk for prostate cancer was independent of smoking.
  • We note that there may be other factors, such as dietary exposures, which may modulate prostate cancer risk in combination with genetic variation within the NAT2 and NER genes.
  • Our results, in combination with previous observations of LOH for ERCC5 in prostate tumors, provide further evidence for a role of XPG/ERCC5 in the etiology of prostate cancer.
  • [MeSH-major] African Americans / ethnology. African Americans / genetics. Arylamine N-Acetyltransferase / genetics. Polymorphism, Single Nucleotide / genetics. Prostatic Neoplasms / ethnology. Prostatic Neoplasms / genetics. Receptors, Cytoplasmic and Nuclear / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026184.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / S06GM08016
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Orphan Nuclear Receptors; 0 / Receptors, Cytoplasmic and Nuclear; 0 / liver X receptor; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


62. Fernando HS, Sanders AJ, Kynaston HG, Jiang WG: WAVE3 is associated with invasiveness in prostate cancer cells. Urol Oncol; 2010 May-Jun;28(3):320-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WAVE3 is associated with invasiveness in prostate cancer cells.
  • We investigated the expression pattern and the effects of manipulating endogenous WAVE3 expression in prostate cancer cells.
  • MATERIALS AND METHODS: Reverse transcriptase-polymerase chain reaction (RT-PCR) of prostate cell lines and immunohistochemical staining of normal and cancer specimens for WAVE3 proteins were done.
  • Immunohistochemistry of prostate tissue specimens showed that the cytoplasm of cancer cells had stronger staining than normal epithelium.
  • CONCLUSIONS: This is the first report on the expression patterns and the functions of WAVE3 in prostate cancer cell lines.
  • This study shows that WAVE3 is pivotal in controlling the invasiveness of prostate cancer cells.
  • [MeSH-major] Neoplasm Invasiveness / genetics. Prostatic Neoplasms / genetics. Prostatic Neoplasms / pathology. Wiskott-Aldrich Syndrome Protein Family / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19395286.001).
  • [ISSN] 1873-2496
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / WASF3 protein, human; 0 / Wiskott-Aldrich Syndrome Protein Family
  •  go-up   go-down


63. Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G, Klocker H, Wasylyk B, Voller M, Aalders T, Schalken JA, Oren M, Rotter V: hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res; 2006 Apr 1;66(7):3531-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis.
  • Prostate cancer is the most commonly diagnosed type of cancer in men, and there is no available cure for patients with advanced disease.
  • In vitro model systems are urgently required to permit the study of human prostate cell differentiation and malignant transformation.
  • Unfortunately, human prostate cells are particularly difficult to convert into continuously growing cultures.
  • We report here the successful immortalization without viral oncogenes of prostate epithelial cells and, for the first time, prostate stromal cells.
  • These cells exhibit a significant pattern of authentic prostate-specific features.
  • In particular, the epithelial cell culture is able to differentiate into glandular buds that closely resemble the structures formed by primary prostate epithelial cells.
  • The stromal cells have typical characteristics of prostate smooth muscle cells.
  • These immortalized cultures may serve as a unique experimental platform to permit several research directions, including the study of cell-cell interactions in an authentic prostate microenvironment, prostate cell differentiation, and most significantly, the complex multistep process leading to prostate cell transformation.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. DNA-Binding Proteins / physiology. Prostate / cytology. Prostate / metabolism. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Telomerase / physiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585177.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


64. Ross LE, Powe BD, Taylor YJ, Howard DL: Physician-patient discussions with african american men about prostate cancer screening. Am J Mens Health; 2008 Jun;2(2):156-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physician-patient discussions with african american men about prostate cancer screening.
  • Prostate cancer is the second leading cancer killer in men.
  • Men in general and African American men in particular face crucial decisions regarding prostate cancer screening and perhaps treatment for this disease.
  • Major health organizations agree that men should discuss prostate cancer screening with their physicians or other health care professionals.
  • The purpose of the study was to examine sociodemographic and other correlates of physician-patient discussions regarding the advantages and disadvantages of the prostate-specific antigen (PSA) test among African American men aged 40 or older.
  • A majority of African American men reported having discussed the advantages and disadvantages of prostate cancer screening and/or testing with their physicians before ordering it, and physician-patient discussions about the PSA test were associated with increased screening in African American men.
  • Inasmuch as African American men have greater prostate cancer incidence and mortality over other groups, future attempts should be made to find meaningful correlates of PSA screening and test use to help reduce the burden of this disease.
  • [MeSH-major] African Americans / statistics & numerical data. Health Knowledge, Attitudes, Practice. Mass Screening / standards. Prostatic Neoplasms / ethnology. Prostatic Neoplasms / prevention & control
  • [MeSH-minor] Adult. Age Factors. Aged. Communication. Confidence Intervals. Cross-Sectional Studies. Educational Status. Health Education / organization & administration. Humans. Male. Men's Health. Middle Aged. Multivariate Analysis. Odds Ratio. Physician-Patient Relations. Prostate-Specific Antigen / blood. Risk Assessment. Socioeconomic Factors. Survival Analysis. United States / epidemiology


65. Chavarro JE, Stampfer MJ, Hall MN, Sesso HD, Ma J: A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality. Am J Clin Nutr; 2008 Nov;88(5):1297-303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality.
  • BACKGROUND: Fish and seafood n-3 fatty acids may prevent or delay the progression of prostate cancer, but epidemiologic studies do not uniformly support this hypothesis.
  • OBJECTIVE: We examined the relation of fish and seafood n-3 fatty acid intakes with prostate cancer incidence and mortality.
  • DESIGN: We conducted a prospective cohort study among 20,167 men participating in the Physician's Health Study who were free of cancer in 1983.
  • RESULTS: During 382 144 person-years of follow-up, 2161 men were diagnosed with prostate cancer and 230 died of prostate cancer.
  • Fish intake was unrelated to prostate cancer incidence.
  • Survival analysis among the men diagnosed with prostate cancer revealed that those consuming fish >or=5 times/wk had a 48% lower risk of prostate cancer death than did men consuming fish less than once weekly [relative risk (RR) = 0.52; 95% CI: 0.30, 0.91; P for trend = 0.05].
  • A similar association was found between seafood n-3 fatty acid intake and prostate cancer mortality (RR(Q5 versus Q1) = 0.64; 95% CI: 0.42, 0.99; P for trend = 0.02).
  • CONCLUSION: These results suggest that fish intake is unrelated to prostate cancer incidence but may improve prostate cancer survival.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):627-30 [9681532.001]
  • [Cites] Nutr Cancer. 1997;29(2):114-9 [9427973.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):1107-13 [10362125.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):591-7 [10408871.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1019-27 [10491529.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2744-54 [15495177.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 May;72(5):363-72 [15850718.001]
  • [Cites] J Clin Oncol. 2005 Nov 10;23(32):8152-60 [16278466.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jan 6;339(1):93-8 [16289380.001]
  • [Cites] Cancer Causes Control. 2006 Mar;17(2):199-208 [16425098.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):203-10 [16492906.001]
  • [Cites] Neoplasia. 2006 Feb;8(2):112-24 [16611404.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):211-8 [17216324.001]
  • [Cites] Cancer Causes Control. 2007 Feb;18(1):41-50 [17315319.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2466-73 [17278090.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1364-70 [17585059.001]
  • [Cites] Am J Clin Nutr. 2008 May;87(5):1405-13 [18469265.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):229-41 [18556778.001]
  • [Cites] Urology. 2008 Dec;72(6):1324-8 [18400281.001]
  • [Cites] Cancer Causes Control. 2006 Aug;17(6):831-41 [16783611.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6):935-45 [15159222.001]
  • [Cites] Br J Cancer. 1999 Dec;81(7):1238-42 [10584888.001]
  • [Cites] Prostate. 2001 Jun 1;47(4):262-8 [11398173.001]
  • [Cites] Lancet. 2001 Jun 2;357(9270):1764-6 [11403817.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1201-6 [11470750.001]
  • [Cites] Am J Clin Nutr. 2001 Oct;74(4):549-54 [11566656.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):719-25 [12163324.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):64-7 [12540506.001]
  • [Cites] Lipids. 2003 Apr;38(4):391-8 [12848284.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1422-8 [14693732.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):367-86 [15141138.001]
  • [Cites] Am J Clin Nutr. 2004 Jul;80(1):204-16 [15213050.001]
  • [Cites] Int J Cancer. 2004 Sep 1;111(3):444-50 [15221975.001]
  • [Cites] Arch Intern Med. 1987 Feb;147(2):361-3 [3813756.001]
  • [Cites] Cancer Res. 1989 Apr 1;49(7):1857-60 [2924323.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):598-604 [2743254.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):129-35 [2664509.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6836-40 [2208150.001]
  • [Cites] Prostate. 1991;18(3):243-54 [2020620.001]
  • [Cites] Am J Epidemiol. 1992 May 15;135(10):1114-26; discussion 1127-36 [1632423.001]
  • [Cites] J Am Diet Assoc. 1993 Jul;93(7):790-6 [8320406.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):281-6 [8158682.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):187-92 [7606192.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1145-9 [8602179.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):889-95 [8922296.001]
  • [Cites] Int J Cancer. 1997 May 16;71(4):545-51 [9178806.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 18;235(2):418-23 [9199209.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13182-7 [9789062.001]
  • (PMID = 18996866.001).
  • [ISSN] 1938-3207
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA042182-20; United States / NCI NIH HHS / CA / CA042182-20; United States / NCI NIH HHS / CA / CA058684-13; United States / NCI NIH HHS / CA / R01 CA090598; United States / NCI NIH HHS / CA / R01 CA058684-13; United States / NCI NIH HHS / CA / CA090598-05S1; United States / NCI NIH HHS / CA / R01 CA058684; United States / NCI NIH HHS / CA / R01 CA042182; United States / NCI NIH HHS / CA / R01 CA090598-05S1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3
  • [Other-IDs] NLM/ NIHMS180899; NLM/ PMC2843087
  •  go-up   go-down


66. Albertsen PC: Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Oncol; 2010 Jul;7(7):394-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of localized prostate cancer: when is active surveillance appropriate?
  • Testing for prostate-specific antigen (PSA) has caused a dramatic increase in the incidence of prostate cancer during the past two decades.
  • Many cancers identified by repeated PSA testing are small volume, low-grade lesions that pose little threat of progression over 15-20 years.
  • Data from a recently reported randomized trial indicate that as many as 48 men must undergo treatment to prevent one prostate cancer-related death.
  • To date, prostate cancer-specific survival is over 99%.
  • For men harboring tumors with a Gleason score >7, data from two recently reported Swedish trials suggest lower prostate cancer-related mortality for those men receiving either surgery or radiation.
  • [MeSH-major] Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / therapy
  • [MeSH-minor] Digital Rectal Examination. Disease Progression. Humans. Male. Prognosis. Prostate-Specific Antigen / blood. Risk Assessment. Survival Rate


67. Pace G, Pomante R, Vicentini C: Sarcoma of prostate: case report and review of the literature. Arch Ital Urol Androl; 2010 Jun;82(2):105-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoma of prostate: case report and review of the literature.
  • OBJECTIVES: Prostate sarcomas are rare entity, the most common is leiomyosarcoma which account for 0.1% of all prostate malignancies.
  • The overall survival rate remains poor regardless of initial tumour size, grade or histological subtype.
  • MATERIALS AND METHODS: We describe a case of a patient affected by sarcoma of prostate.
  • Furthermore, we reviewed the cases of prostate sarcomas available in literature to clarify the best therapeutic options to be applied.
  • CONCLUSIONS: Prostate sarcomas are highly aggressive, with limited therapeutic options.
  • An early diagnosis and complete surgical excision with negative margins offer patients the long-term disease free survival.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20812534.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 27
  •  go-up   go-down


68. Skaudickas D, Kondrotas AJ, Kevelaitis E, Venskutonis PR: The effect of Echinacea purpurea (L.) Moench extract on experimental prostate hyperplasia. Phytother Res; 2009 Oct;23(10):1474-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of Echinacea purpurea (L.) Moench extract on experimental prostate hyperplasia.
  • Moench) on the prostate gland of rats using an experimental model of benign prostate hyperplasia (BPH).
  • The animals were administered 50 mg/kg of extract preparation for 4 and 8 weeks and the prostate mass and structural degenerative changes were evaluated in the course of the experiment.
  • The administration of E. purpurea extract to rats with hyperplasia for 4 and 8 weeks gradually and significantly reduced the prostate mass and reversed the degenerative changes in the structure of the prostate gland.
  • [MeSH-major] Echinacea. Phytotherapy. Plant Extracts / therapeutic use. Prostate / drug effects. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19288499.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Plant Extracts
  •  go-up   go-down


69. Knight SJ, Latini DM: Sexual side effects and prostate cancer treatment decisions: patient information needs and preferences. Cancer J; 2009 Jan-Feb;15(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sexual side effects and prostate cancer treatment decisions: patient information needs and preferences.
  • Prostate cancer treatment decision making requires complex trade-offs among treatment outcomes, and sexual function is a central consideration for most men.
  • Although sexual function is included in prostate cancer decision models, survival and fear of recurrence and cancer progression weigh more heavily in these decisions for many men than concerns about treatment impact on sexuality.
  • In this article, we discuss the importance of sexuality in men's treatment decisions for prostate cancer.
  • We focus on men's preferences for maintaining sexual function and their needs for information about the risk of sexual side effects with prostate cancer treatment.
  • Our review suggests that among men diagnosed with prostate cancer sexual function is less important to men than concerns about survival, but is more highly valued than other side effects and treatment characteristics.
  • However, there is evidence that concerns about sexuality are not in proportion with the associated risk for sexual problems with prostate cancer treatment and men acknowledge unmet needs for information about sexuality in making prostate cancer treatment decisions.
  • [MeSH-major] Needs Assessment. Patient Education as Topic. Prostatic Neoplasms / therapy. Sexual Dysfunction, Physiological / etiology


70. Ruhayel Y, Giwercman A, Ulmert D, Rylander L, Bjartell A, Manjer J, Berglund G, Giwercman YL: Male infertility and prostate cancer risk: a nested case-control study. Cancer Causes Control; 2010 Oct;21(10):1635-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male infertility and prostate cancer risk: a nested case-control study.
  • The pathogenesis of prostate cancer is unclear, although experimental evidence implicates androgens as playing an important role.
  • Infertile men frequently suffer from some degree of hypogonadism and may hence be hypothesized to be at lower risk of developing prostate cancer than fertile men.
  • To test this hypothesis, we conducted a case-control study nested within "the Malmö Diet and Cancer Study" cohort in Sweden, inviting 661 prostate cancer cases and 661 age-matched controls to participate.
  • Thus, 891 men were included, providing 445 prostate cancer cases and 446 controls.
  • Logistic regression showed that the infertile men were at significantly lower risk of being diagnosed with prostate cancer than the fertile men (odds ratio, 0.45; 95% confidence interval, 0.25-0.83).
  • We conclude that enduring male infertility is associated with a reduced prostate cancer risk, thus corroborating the theory that normal testicular function, and hence most probably sufficient steroidogenesis, is an important contributing factor to the later development of this malignancy.
  • [MeSH-major] Fertility. Infertility, Male. Prostatic Neoplasms / epidemiology


71. Rouvière O: [MRI of the prostate: optimization of imaging protocols]. J Radiol; 2006 Feb;87(2 Pt 2):210-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MRI of the prostate: optimization of imaging protocols].
  • [Transliterated title] IRM de la prostate: optimisation des protocoles techniques.
  • This article details the imaging protocols for prostate MRI and the influence on image quality of each particular setting: type of coils to be used (endorectal or external phased-array coils?
  • [MeSH-major] Adenocarcinoma / diagnosis. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Artifacts. Biopsy. Clinical Protocols. Contrast Media. Follow-Up Studies. Humans. Image Enhancement. Lymphatic Metastasis / diagnosis. Male. Positron-Emission Tomography. Prostate / pathology. Prostatectomy. Time Factors. Treatment Outcome. Ultrasonic Therapy

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484946.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 42
  •  go-up   go-down


72. Schostak M, Christoph F, Schrader M, Panick M, Lingnau A, Miller K: [Prostate biopsy -- practical examination of the adequacy of Chen's virtual strategy]. Aktuelle Urol; 2005 Apr;36(2):149-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate biopsy -- practical examination of the adequacy of Chen's virtual strategy].
  • [Transliterated title] Prostatabiopsie -- Chens virtuelles Schema in der Praxis.
  • INTRODUCTION: Prostate sextant biopsy is considered the gold standard of invasive prostate cancer diagnostics.
  • MATERIAL AND METHOD: Ultrasound-guided ten-core prostate biopsies are performed in our department.
  • Following the model of Chen, three prostate biopsies instead of on are taken from the middle plane.
  • RESULTS: Between July 2003 and February 2004, 191 patients scheduled for a 10-core prostate biopsy were included in the study.
  • A carcinoma was detected in 61/176 (34.7 %) of the patients.
  • The carcinoma was found only in the standard sextant localisations (27.8 %) in 17/61 patients and additionally in the paraurethral or ventral region in 35/61 (57.3 %).
  • The carcinoma was located only paraurethrally in 1/62 (1.6 %) and only ventrally in 6/62 (9.7 %).
  • Altogether, the prostate carcinoma was detected only by the additional biopsies in 6 patients (9.8 %).
  • A carcinoma was detected most frequently in the following biopsies: base right (17.1 %), central lat. right (17.5 %) and apex right (16.5 %) and most rarely paraurethral right (12 %) and ventral right (10.2 %).
  • [MeSH-major] Biopsy, Needle / methods. Computer Simulation. Endosonography. Imaging, Three-Dimensional. Prostate / pathology. Prostatic Neoplasms / pathology. User-Computer Interface

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902576.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


73. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science; 2005 Oct 28;310(5748):644-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
  • Two ETS transcription factors, ERG and ETV1, were identified as outliers in prostate cancer.
  • We identified recurrent gene fusions of the 5' untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression.
  • By using fluorescence in situ hybridization, we demonstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or ETV1.
  • Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer.
  • These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer.
  • [MeSH-major] DNA-Binding Proteins / genetics. Membrane Proteins / genetics. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Prostatic Neoplasms / genetics. Serine Endopeptidases / genetics. Trans-Activators / genetics. Transcription Factors / genetics
  • [MeSH-minor] Androgens / metabolism. Cell Line, Tumor. Gene Expression Regulation, Neoplastic. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Molecular Sequence Data. Polymerase Chain Reaction. Translocation, Genetic


74. Yamashita S, Takahashi S, McDonell N, Watanabe N, Niwa T, Hosoya K, Tsujino Y, Shirai T, Ushijima T: Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers. Cancer Res; 2008 Apr 1;68(7):2112-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers.
  • To identify methylation-silenced genes in prostate cancers, a microarray analysis for genes up-regulated by treatment with a demethylating agent, 5-aza-2'-deoxycytidine, was performed using three rat prostate cancer cell lines.
  • Eight genes (Aebp1, Dysf, Gas6, LOC361288, Nnat, Ocm, RGD1308119, and Tgfbr2) were re-expressed at 16-fold or more, and their promoter CpG islands were shown to be densely methylated in the cancer cell lines.
  • From the eight genes, Tgfbr2, a key mediator of transforming growth factor-beta (TGF-beta) signaling that has been strongly implicated in human and rat prostate carcinogenesis, was selected, and its silencing in primary samples was analyzed further.
  • Tgfbr2 was methylated and markedly down-regulated in three of seven 3,2'-dimethyl-4-aminobiphenyl-induced invasive adenocarcinomas in the dorsolateral lobe of the rat prostate.
  • In humans, marked down-regulation of TGFBR2 protein was observed in 12 of 20 high-grade prostatic intraepithelial neoplasia and 36 of 60 prostate cancers.
  • DNA methylation of the human TGFBR2 promoter CpG islands repressed transcription, if present, but neither methylation nor mutation were detected in 27 human prostate cancers analyzed.
  • The identification of methylation silencing of Tgfbr2 in rat prostate cancers, in accordance with TGFBR2 down-regulation in human prostate cancers, will enable us to analyze how aberrant methylation is induced in vivo and identify factors that promote and suppress the induction of aberrant methylation.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Gene Silencing. Prostatic Neoplasms / genetics. Protein-Serine-Threonine Kinases / genetics. Receptors, Transforming Growth Factor beta / genetics

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381416.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 0 / Receptors, Transforming Growth Factor beta; 776B62CQ27 / decitabine; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor; M801H13NRU / Azacitidine
  •  go-up   go-down


75. Bahn DK, Silverman P, Lee F Sr, Badalament R, Bahn ED, Rewcastle JC: Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol; 2006 Sep;20(9):688-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal prostate cryoablation: initial results show cancer control and potency preservation.
  • BACKGROUND: Focal prostate cryoablation is the less-than-complete ablation of the gland with ice.
  • Known tumor is ablated aggressively, whereas contralateral prostate tissue and surrounding structures are spared.
  • This method offers targeted local cancer control aiming at sexual potency and urinary continence preservation in patients whose prostate cancer is believed to be unilateral.
  • PATIENTS AND METHODS: Patients who had a strong desire for preservation of sexual function and continence were informed of focal prostate cryoablation as an investigational treatment option for clinically organ-confined, unilateral tumor identified by color Doppler ultrasonography and confirmed by targeted and systematic biopsy.
  • Only stage, not preoperative serum prostate specific antigen concentration (PSA) or tumor differentiation, was considered a potential contraindication.
  • The one biopsy-positive patient was subsequently treated with full-gland cryoablation and remains disease free.
  • CONCLUSION: Focal cryoablation can provide biochemical and local control of prostate cancer while preserving potency and continence.


76. Loeb S, Sutherland DE, D'Amico AV, Roehl KA, Catalona WJ: PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology; 2008 Nov;72(5):1116-20; discussion 1120
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
  • OBJECTIVES: Conflicting evidence has been reported on the association of prostate-specific antigen velocity (PSAV) with Gleason score in prostate needle biopsy specimens.
  • The Gleason score is an important prognostic indicator for men with prostate cancer, and, in modern practice, it frequently affects treatment decisions.
  • CONCLUSIONS: Our results have further validated PSAV as a marker for prostate cancer aggressiveness.
  • Thus, PSAV could be useful in treatment decision-making and in assessing the likelihood of long-term cancer control in men with prostate cancer.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology


77. Ueda Y, Higuchii Y, Hashimoto T, Mitsui Y, Maruyamai T, Kondou N, Nojima M, Yamamoto S, Shincho M, Hirota S, Shima H: [Prostate cancer diagnosed through the biopsy of the bone metastatic lesion; a case report]. Hinyokika Kiyo; 2007 May;53(5):327-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate cancer diagnosed through the biopsy of the bone metastatic lesion; a case report].
  • Although digital rectal examination was normal, a high serum prostate specific antigen (PSA) level (85.9 ng/ml) led us to perform sextant prostate biopsy, resulting in negative for cancer.
  • Three months later, since the serum PSA increased to 169 ng/ml with high serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 levels.
  • Twelve-core prostate biopsy was performed again, but the result was negative.
  • Pelvic magnetic resonance imaging (MRI) showed a metastatic lesion on the right pubic bone, which was biopsied, and turned out to be poorly differentiated prostate cancer in histology.
  • To our knowledge, there were only two case reports diagnosed as prostate cancer by biopsies of the metastatic lesions in Japanese literature, but none in the English literature.
  • These findings suggest that high serum levels of CEA and CA19-9 in patients with prostate cancer are indications of hormone-refractory prostate cancer resulting in poor prognosis.
  • [MeSH-major] Bone Neoplasms / secondary. Bone and Bones / pathology. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biopsy. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Humans. Male. Prostate / pathology. Prostate-Specific Antigen / blood


78. Drewa T, Styczynski J: Progenitor cells are responsible for formation primary epithelial cultures in the prostate epithelial model. Int Urol Nephrol; 2007;39(3):851-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progenitor cells are responsible for formation primary epithelial cultures in the prostate epithelial model.
  • We hypothesized prostate epithelial CD133-positive ASC to be responsible for establishing the primary cell culture.
  • The prostate epithelial stem cells were isolated using anti-CD133 microbeads in order to form different cell populations.
  • The morphology of cultures developed from CD133(+) and CD133(-) prostate epithelial cells were compared with prostate epithelium cell culture obtained after simple isolation procedure.
  • Double CD133(+) and CD133(-) cultures from two rats were established after enzymatic digestion and positive selection by SuperMACS device, and two non-selected CD133(+)/CD133(-) cultures were developed by simple prostate epithelial cell isolation from two other rats.
  • It was observed that growth of the CD133(+)/CD133(-) and CD133(+)culture resembled epithelial-like prostate cell culture.
  • We concluded that the epithelial progenitor cells are responsible for establishing primary prostate epithelial cultures in vitro.
  • [MeSH-major] Neoplastic Stem Cells / metabolism. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11896-903 [12909713.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):196-205 [14689591.001]
  • [Cites] Dev Biol. 2006 Feb 1;290(1):66-80 [16360140.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1480-5 [16432235.001]
  • [Cites] Prostate. 1999 Nov 1;41(3):173-80 [10517875.001]
  • [Cites] Cell Prolif. 2005 Dec;38(6):363-74 [16300650.001]
  • [Cites] Lab Invest. 2000 Aug;80(8):1251-8 [10950116.001]
  • [Cites] Urol Oncol. 2006 Mar-Apr;24(2):119-21 [16520275.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):19-47 [15788637.001]
  • [Cites] Urol Oncol. 2006 Mar-Apr;24(2):131-40 [16520277.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):794-802 [16424011.001]
  • [Cites] Stem Cells. 2006 Aug;24(8):1859-68 [16644920.001]
  • [Cites] Eur J Cell Biol. 2005 Mar;84(2-3):341-54 [15819412.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 [15226377.001]
  • [Cites] Cytometry A. 2003 Aug;54(2):89-99 [12879455.001]
  • [Cites] Lab Invest. 2000 Aug;80(8):1243-50 [10950115.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 16;338(2):1164-70 [16286093.001]
  • [Cites] Prostate. 2002 Feb 15;50(3):189-201 [11813211.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1769-75 [11106548.001]
  • [Cites] Prostate. 2002 Jan 1;50(1):46-53 [11757035.001]
  • [Cites] Cell Cycle. 2006 Jan;5(2):138-41 [16357539.001]
  • [Cites] Prostate. 1986;8(1):51-61 [2418431.001]
  • [Cites] J Cell Sci. 2006 Apr 1;119(Pt 7):1416-24 [16554439.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] Histol Histopathol. 2006 Sep;21(9):995-1027 [16763950.001]
  • [Cites] Nat Methods. 2006 Mar;3(3):179-81 [16489334.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2004;7(1):73-83 [14999242.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8135-42 [11719442.001]
  • (PMID = 17318344.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / AC133 Antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 0 / Prom1 protein, rat
  •  go-up   go-down


79. Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal JL, Zimmerman CN, Kozikowski AP, Barrett JA, Eckelman WC, Babich JW: A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem; 2009 Jan 22;52(2):347-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer.
  • Prostate specific membrane antigen (PSMA) is a validated molecular marker for prostate cancer.
  • Two lead iodine compounds were radiolabeled with (123)I and (131)I and demonstrated specific PSMA binding on human prostate cancer cells, warranting evaluation as radioligands for the detection, staging, and monitoring of prostate cancer.
  • [MeSH-major] Glutamate Carboxypeptidase II / antagonists & inhibitors. Halogens / chemistry. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • BindingDB. BindingDB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111054.001).
  • [ISSN] 1520-4804
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / 1R43EB004253
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Halogens; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


80. Denis LJ: Europa Uomo: The European Prostate Cancer Coalition. Arch Ital Urol Androl; 2006 Dec;78(4):157-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Europa Uomo: The European Prostate Cancer Coalition.
  • The European Prostate Cancer Coalition is an independent, international, non-profit association of patient led prostate cancer support groups.
  • The European survivors of prostate cancer, now about one million strong, have taken up their responsibility to get involved in the support the control of the disease and focus on prevention, optimal treatment and quality of life.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17269623.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


81. Stock D, Groome PA, Siemens DR: Inflammation and prostate cancer: a future target for prevention and therapy? Urol Clin North Am; 2008 Feb;35(1):117-30; vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammation and prostate cancer: a future target for prevention and therapy?
  • Given its long natural history, prostate cancer has become an ideal model for the clinical and basic science study of neoplastic disease in distinct pathologic phases: tumor initiation, progression, invasion, and metastasis.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs), because of their ability to attenuate inflammation, as well as possibly direct anti-cancer properties associated with the inhibition of stromal cyclooxygenase-2, are potential candidates for clinical use in prostate cancer.
  • Though epidemiologic evidence indicating a reduced risk of prostate cancer for NSAID users supports a chemoprotective benefit, observational assessment and clinical trials of these agents among large cohorts of prostate cancer patients are needed to determine their value in prostate cancer management.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Inflammation / drug therapy. Inflammation / pathology. Prostatic Neoplasms / pathology. Prostatic Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061030.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  • [Number-of-references] 117
  •  go-up   go-down


82. Fang J, Zhou Q, Shi XL, Jiang BH: Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis; 2007 Mar;28(3):713-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
  • Insulin-like growth factor 1 receptor (IGF-1R) activation is required for prostate cell proliferation.
  • Prostate cancer is one of the most commonly diagnosed malignant tumors in Western countries.
  • Overexpression of IGF-1R in prostate cancer is associated with tumor growth.
  • With evidence accumulating for a chemopreventive role of flavonoids, the effects of luteolin, a bioactive flavonoid, on IGF-1R signaling in prostate cancer cells were examined.
  • Luteolin inhibited insulin-like growth factor 1 (IGF-1) induced activation of IGF-1R and AKT in prostate cancer PC-3 and DU145 cells.
  • As a result, luteolin suppressed proliferation and induced apoptosis of prostate cancer cells.
  • Knockdown of IGF-1R by siRNA led to inhibition of proliferation of prostate cancer cells.
  • Our results provide a new insight into the mechanisms that luteolin is against cancer cells.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Cell Cycle / drug effects. Luteolin / pharmacology. Prostatic Neoplasms / pathology. Receptor, IGF Type 1 / antagonists & inhibitors


83. Brouwer IA: Omega-3 PUFA: good or bad for prostate cancer? Prostaglandins Leukot Essent Fatty Acids; 2008 Sep-Nov;79(3-5):97-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omega-3 PUFA: good or bad for prostate cancer?
  • INTRODUCTION: The objective of this meta-analysis was to estimate quantitatively the associations between intake or status of omega-3 polyunsaturated (omega-3 PUFA) fatty acids and occurrence of prostate cancer in observational studies in humans.
  • RESULTS: The combined estimate showed an increased risk of prostate cancer in men with a high intake or blood level of alpha-linolenic acid (ALA) (combined relative risk (RR) 1.36; 95% CI 1.08-1.70).
  • Ecosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were not significantly associated with prostate cancer.
  • DISCUSSION: The association between high intake of ALA and prostate cancer is of concern and needs further study.
  • However, the fact that the prospective studies do not show a clear association makes a true effect of intake of ALA on prostate cancer less likely.
  • [MeSH-major] Fatty Acids, Omega-3 / blood. Prostatic Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951003.001).
  • [ISSN] 0952-3278
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3; 0RBV727H71 / alpha-Linolenic Acid; 25167-62-8 / Docosahexaenoic Acids
  • [Number-of-references] 20
  •  go-up   go-down


84. Marrari A, Iero M, Pilla L, Villa S, Salvioni R, Valdagni R, Parmiani G, Rivoltini L: Vaccination therapy in prostate cancer. Cancer Immunol Immunother; 2007 Apr;56(4):429-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination therapy in prostate cancer.
  • Radical prostatectomy and radiation therapy provide excellent localized prostate cancer (PC) control.
  • Although the majority of prostate carcinoma is nowadays diagnosed at early stages with favourable risk features, in patients up to 30-40% it recurs within 10 years.
  • Furthermore, the lack of effective therapies, once prostate carcinoma becomes refractory to androgen deprivation, mandates the development of alternative therapeutic options.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Prostatic Neoplasms / immunology. Prostatic Neoplasms / therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031640.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 143
  •  go-up   go-down


85. Korkes F, Gasperini R, Korkes KL, Silva Neto DC, Castro MG: Testicular metastases: a poor prognostic factor in patients with advanced prostate cancer. World J Urol; 2009 Feb;27(1):113-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular metastases: a poor prognostic factor in patients with advanced prostate cancer.
  • PURPOSE: Prostate cancer is the most frequently diagnosed neoplasm in men.
  • Testicular metastases from prostate cancer are rare events that have been previously reported; however, its frequency and clinical meaning are not well established.
  • PATIENTS AND METHODS: A review of patients who underwent androgen deprivation orchidectomy for prostate cancer between 1995 and 2007 was undertaken.
  • In such context, evaluation of testicular parenchyma of patients with advanced prostate cancer could be assessed.
  • RESULTS: Of the 1,693 orchidectomies performed during the period analysed, three cases of testicular metastases of prostate cancer (range 58-76 years) were diagnosed (0.18%).
  • CONCLUSION: In conclusion, testicular metastases from prostate cancer are a rare event, observed in 1.8 per 1,000 cases.
  • [MeSH-major] Prostatic Neoplasms / pathology. Testicular Neoplasms / secondary


86. Wu YJ, Liang CH, Zhou FJ, Gao X, Chen LW, Liu Q: [A case-control study of environmental and genetic factors and prostate cancer in Guangdong]. Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Jul;43(7):581-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case-control study of environmental and genetic factors and prostate cancer in Guangdong].
  • OBJECTIVE: To explore the etiologic relationship of prostate cancer and environmental and genetic polymorphism in southern China METHODS: A hospital-based and 1:1 matched case-control study was conducted.
  • The blood samples were collected from 85 cases of prostate cancer and 82 controls of other diseases after informing consent.
  • RESULTS: An increased risk of prostate cancer development was observed with the early first spermatorrhea (age < 18) (OR = 2.90, 95% CI: 1.76 - 4.80), early first sexual intercourse (age < or = 24) (OR = 2.38, 95% CI: 1.14 - 4.96), frequent sexual intercourse before 35 year old (OR = 1.80, 95% CI: 1.19 - 2.70), family history of cancer (OR = 2.70, 95% CI: 1.31 - 5.58), more intake of pork (OR =2.27, 95% CI: 1.38 - 3.70).
  • CYP17 A1/A2 and CYP17 A2/A2 genotypes were related with a high risk of prostate cancer and OR values of 1.78 (95% CI: 0.70 - 4.53) and 2.57 (95% CI: 0.91 - 7.25) respectively.
  • Study also showed that there was an interaction between CYP17 polymorphisms and early first spermatorrhea and family cancer history related to the risk of prostate cancer with OR value at 13.35 (95% CI: 1.58 - 113.00) and 4.01 (95% CI: 1.22 - 13.17) respectively.
  • CONCLUSION: Sexual intercourse, dietary intake and family cancer history should be related to prostate cancer occurrence.
  • CYP17 polymorphism might be associated with a high risk of prostate cancer.
  • It suggests that there are multiple environmental and genetic factors to the prostate cancer.
  • [MeSH-major] Environmental Exposure. Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / genetics. Steroid 17-alpha-Hydroxylase / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954068.001).
  • [ISSN] 0253-9624
  • [Journal-full-title] Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
  • [ISO-abbreviation] Zhonghua Yu Fang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.14.99.9 / CYP17A1 protein, human; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase
  •  go-up   go-down


87. Salinas CA, Koopmeiners JS, Kwon EM, FitzGerald L, Lin DW, Ostrander EA, Feng Z, Stanford JL: Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate; 2009 Mar 1;69(4):363-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.
  • BACKGROUND: A recent report suggests that the combination of five single-nucleotide polymorphisms (SNPs) at 8q24, 17q12, 17q24.3 and a family history of the disease may predict risk of prostate cancer.
  • The present study tests the performance of these factors in prediction models for prostate cancer risk and prostate cancer-specific mortality.
  • Cox proportional hazards models estimated hazard ratios for prostate cancer-specific mortality according to genotypes.
  • RESULTS: The combination of SNP genotypes and family history was significantly associated with prostate cancer risk (p(trend) = 1.5 x 10(-20)).
  • Neither the individual nor combined risk factors was associated with prostate cancer-specific mortality.
  • CONCLUSION: Genotypes for five SNPs plus family history are associated with a significant elevation in risk for prostate cancer and may explain up to 45% of prostate cancer in our population.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Wiley-Liss, Inc.
  • [Cites] J Natl Cancer Inst. 1951 Jun;11(6):1269-75 [14861651.001]
  • [Cites] J Clin Epidemiol. 1994 Aug;47(8):881-9 [7730891.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14068-73 [16945910.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2944-50 [17409399.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2951-6 [17409400.001]
  • [Cites] Nat Genet. 2007 May;39(5):645-9 [17401363.001]
  • [Cites] Nat Genet. 2007 May;39(5):638-44 [17401364.001]
  • [Cites] Nat Genet. 2007 May;39(5):631-7 [17401366.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):977-83 [17603485.001]
  • [Cites] Genome Res. 2007 Dec;17(12):1717-22 [17978284.001]
  • [Cites] N Engl J Med. 2008 Feb 28;358(9):910-9 [18199855.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):310-5 [18264096.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):316-21 [18264097.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):382-3, 386 [18334700.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1203-13 [18483343.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):250-60 [18556686.001]
  • [Cites] Biostatistics. 2008 Oct;9(4):621-34 [18310059.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):881-6 [10548316.001]
  • [Cites] BMJ. 1999 Dec 11;319(7224):1562-5 [10591726.001]
  • [Cites] Am J Epidemiol. 2004 May 1;159(9):882-90 [15105181.001]
  • [Cites] Br J Prev Soc Med. 1971 Nov;25(4):242-4 [5160433.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Am J Epidemiol. 1988 Apr;127(4):857-63 [3354550.001]
  • [Cites] Nat Genet. 2006 Jun;38(6):652-8 [16682969.001]
  • (PMID = 19058137.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097186; United States / NCI NIH HHS / CA / R01 CA056678; United States / NCI NIH HHS / CA / R01 CA56678; United States / NCI NIH HHS / CA / R01 CA082664; United States / NCI NIH HHS / CA / R01 CA092579; United States / NCI NIH HHS / CA / R01 CA056678-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS105496; NLM/ PMC2788301
  •  go-up   go-down


88. Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, Chen H, Sun X, Boothman DA, Min W, Hsieh JT: Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A; 2010 Feb 09;107(6):2485-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis.
  • A single nucleotide polymorphism in the DAB2IP gene is associated with risk of aggressive prostate cancer (PCa), and loss of DAB2IP expression is frequently detected in metastatic PCa.
  • Here, we show that the loss of DAB2IP expression initiates epithelial-to-mesenchymal transition (EMT), which is visualized by repression of E-cadherin and up-regulation of vimentin in both human normal prostate epithelial and prostate carcinoma cells as well as in clinical prostate-cancer specimens.
  • In DAB2IP knockout mice, prostate epithelial cells exhibited elevated mesenchymal markers, which is characteristic of EMT.
  • Using a human prostate xenograft-mouse model, we observed that knocking down endogenous DAB2IP in human carcinoma cells led to the development of multiple lymph node and distant organ metastases.
  • [MeSH-major] Epithelial Cells / pathology. Mesoderm / pathology. Prostatic Neoplasms / pathology. ras GTPase-Activating Proteins / physiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Jan 27;19(4):537-45 [10698523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19878-83 [19903888.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3650-4 [10910081.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32475-81 [10913153.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):66-73 [11148561.001]
  • [Cites] Oncogene. 2001 Jan 11;20(2):252-9 [11313952.001]
  • [Cites] Eur J Cancer. 2001 Aug;37(12):1475-81 [11506953.001]
  • [Cites] Bioessays. 2001 Oct;23(10):912-23 [11598958.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jan;41(1):11-28 [11796229.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12622-31 [11812785.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45847-53 [12235165.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):3121-30 [12446720.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):28-33 [12573432.001]
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):847-57 [14623871.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] Exp Cell Res. 2004 Feb 15;293(2):267-74 [14729464.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2082-9 [15041729.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:781-810 [15473860.001]
  • [Cites] J Biol Chem. 2004 Oct 22;279(43):44955-65 [15310755.001]
  • [Cites] Cancer Res. 1984 Aug;44(8):3522-9 [6744277.001]
  • [Cites] Biochem J. 1993 Sep 15;294 ( Pt 3):625-9 [8397507.001]
  • [Cites] Biochem J. 1994 Oct 1;303 ( Pt 1):21-6 [7945242.001]
  • [Cites] J Biol Chem. 1995 Nov 3;270(44):26123-8 [7592815.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 29;247(3):851-8 [9647782.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1627-36 [9816342.001]
  • [Cites] Science. 1999 Mar 26;283(5410):2089-91 [10092233.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):59-66 [15386433.001]
  • [Cites] Br J Cancer. 2005 Mar 28;92(6):1117-25 [15770214.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(2):119-26 [15809669.001]
  • [Cites] EMBO J. 2005 Apr 20;24(8):1571-83 [15791206.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22437-44 [15817459.001]
  • [Cites] Mol Cell. 2005 Jul 22;19(2):159-70 [16039586.001]
  • [Cites] Gene. 2005 Nov 21;361:1-12 [16185824.001]
  • [Cites] Prostate. 2006 Feb 1;66(2):193-9 [16173043.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2490-6 [17363566.001]
  • [Cites] J Hepatol. 2007 Apr;46(4):655-63 [17258345.001]
  • [Cites] J Natl Cancer Inst. 2007 Dec 19;99(24):1836-44 [18073375.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Circ Res. 2008 Apr 11;102(7):840-8 [18292600.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3645-54 [18483246.001]
  • [Cites] Dev Cell. 2008 Jun;14(6):818-29 [18539112.001]
  • [Cites] J Clin Invest. 2008 Dec;118(12):3904-16 [19033661.001]
  • [Cites] Biochim Biophys Acta. 2009 Jan;1795(1):1-15 [18588945.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1438-49 [19487820.001]
  • [Cites] Cell. 2009 Jul 10;138(1):51-62 [19576624.001]
  • [CommentIn] Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2731-2 [20145111.001]
  • (PMID = 20080667.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102792; United States / NCI NIH HHS / CA / U24CA126608; United States / NCI NIH HHS / CA / P30 CA142543; United States / NIAID NIH HHS / AI / 5U19AI067773-04; United States / NIAID NIH HHS / AI / U19 AI067773; United States / NCI NIH HHS / CA / U24 CA126608; United States / NCI NIH HHS / CA / R01 CA139217
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / DAB2IP protein, human; 0 / RNA, Small Interfering; 0 / TCF Transcription Factors; 0 / Vimentin; 0 / beta Catenin; 0 / ras GTPase-Activating Proteins
  • [Other-IDs] NLM/ PMC2823864
  •  go-up   go-down


89. Noel C, Parikh PJ, Roy M, Kupelian P, Mahadevan A, Weinstein G, Enke C, Flores N, Beyer D, Levine L: Prediction of intrafraction prostate motion: accuracy of pre- and post-treatment imaging and intermittent imaging. Int J Radiat Oncol Biol Phys; 2009 Mar 1;73(3):692-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of intrafraction prostate motion: accuracy of pre- and post-treatment imaging and intermittent imaging.
  • PURPOSE: To evaluate whether pre- and post-treatment imaging (immediately before and after a radiation therapy treatment fraction) and intermittent imaging (at intervals during a treatment fraction) are accurate predictors of prostate motion during the delivery of radiation.
  • METHODS AND MATERIALS: The Calypso 4D Localization System was used to continuously track the prostate during radiation delivery in 35 prostate cancer patients, for a total of 1,157 fractions (28-45 per patient).
  • Predictions of prostate motion away from isocenter were modeled for a pre- and post-treatment imaging schedule and for multiple intermittent intrafraction imaging schedules and compared with the actual continuous tracking data.
  • The endpoint was drift of the prostate beyond a certain radial displacement for a duration of more than 30 s, 1 min, and 2 min.
  • Results were used to evaluate the sensitivity and specificity of these models as an evaluation of intrafraction prostate motion.
  • RESULTS: The sensitivity of pre- and post-treatment imaging in determining 30 s of intrafraction prostate motion greater than 3, 5, or 7 mm for all fractions was low, with values of 53%, 49%, and 39%, respectively.
  • CONCLUSIONS: These results suggest that pre- and post-treatment imaging is not a sensitive method of assessing intrafraction prostate motion, and that intermittent imaging is sufficiently sensitive only at a high sampling rate.
  • These findings support the value of continuous, real-time tracking in prostate cancer radiation therapy.
  • [MeSH-major] Electromagnetic Fields. Movement. Prostate. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Electromagnetic Fields.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692324.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Hua LX, Wu HF, Sui YG, Zhang W, Qian LX, Song NH, Zhang JX: [High intensity focused ultrasound combined with endocrine therapy in treating prostate cancer]. Zhonghua Nan Ke Xue; 2005 Mar;11(3):195-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High intensity focused ultrasound combined with endocrine therapy in treating prostate cancer].
  • OBJECTIVE: To evaluate the clinical efficacy of high intensity focused ultrasound (HIFU) combined with endocrine therapy in the treatment of patients with prostate cancer.
  • METHODS: Twenty patients with prostate cancer were treated with extracorporeal HIFU device( model FEP-BY01 ) and androgen ablation, of whom 15 received orchiectomy and 5 LHRH-a.
  • Before and after the treatment, the prostate volume, prostate specific antigen (PSA), international prostate symptom score (IPSS) and maximal flow rate (Qmax) of the patients were (36.4 +/- 16.2) ml and (20.6 +/- 11.8) ml (P < 0.05), (32.2 +/- 10.4) ng/ml and (2.4 +/- 0.8) ng/ml (P < 0.01), 20.
  • CONCLUSION: HIFU combined with endocrine therapy is effective in the treatment of prostate canc-
  • [MeSH-major] Prostatic Neoplasms / therapy. Ultrasound, High-Intensity Focused, Transrectal

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804111.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; 76W6J0943E / Flutamide
  •  go-up   go-down


91. Vanaja DK, Grossmann ME, Cheville JC, Gazi MH, Gong A, Zhang JS, Ajtai K, Burghardt TP, Young CY: PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest; 2009 Mar;27(3):264-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PDLIM4, an actin binding protein, suppresses prostate cancer cell growth.
  • We investigated the molecular function of PDLIM4 in prostate cancer cells.
  • PDLIM4 mRNA and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and PC3 prostate cancer cells.
  • The re-expression of PDLIM4 in prostate cancer cells has significantly reduced the cell growth and clonogenicity with G1 phase of cell-cycle arrest.
  • These results suggest that PDLIM4 may function as a tumor suppressor, involved in the control of cell proliferation by associating with actin in prostate cancer cells.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Feb 1;19(3):359-69 [10654935.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Dec 21;364(3):589-94 [17964547.001]
  • [Cites] Eur J Cell Biol. 2000 Apr;79(4):283-93 [10826496.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5296-302 [11016661.001]
  • [Cites] Cancer Invest. 2001;19(1):28-34 [11291553.001]
  • [Cites] Oncogene. 2001 May 17;20(22):2844-53 [11420696.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5974-8 [11507037.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Mol Biol Cell. 2002 Apr;13(4):1408-16 [11950948.001]
  • [Cites] J Cell Sci. 2002 May 15;115(Pt 10):2067-73 [11973348.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4499-506 [12154061.001]
  • [Cites] Metabolism. 2003 Jun;52(6):675-8 [12800090.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3877-82 [12873976.001]
  • [Cites] Exp Cell Res. 2004 Feb 1;293(1):117-28 [14729062.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):798-804 [15252854.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5484-8 [8516290.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1225-31 [9214606.001]
  • [Cites] J Cell Biol. 1997 Oct 20;139(2):507-15 [9334352.001]
  • [Cites] Genomics. 1997 Dec 1;46(2):291-3 [9417918.001]
  • [Cites] Gene. 1998 Apr 14;210(2):239-45 [9573374.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):8316-21 [10075738.001]
  • [Cites] Mol Biol Cell. 1999 Jun;10(6):1973-84 [10359609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16531-6 [15542589.001]
  • [Cites] Mol Biol Rep. 2004 Dec;31(4):203-15 [15663004.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):796-801 [15720806.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1244-50 [15735008.001]
  • [Cites] J Cell Sci. 2005 Apr 15;118(Pt 8):1663-71 [15797923.001]
  • [Cites] Mol Biol Rep. 2005 Jun;32(2):67-77 [16022279.001]
  • [Cites] Genome Biol. 2005;6(9):R76 [16168083.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1128-36 [16489065.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1997-2005 [17332327.001]
  • [Cites] Circ Res. 2007 Mar 30;100(6):782-94 [17395884.001]
  • [Cites] J Neurosci. 2007 Apr 18;27(16):4313-25 [17442815.001]
  • [Cites] Nature. 2007 May 31;447(7144):596-600 [17515921.001]
  • [Cites] ScientificWorldJournal. 2007;7:1470-92 [17767364.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11100-5 [10753915.001]
  • (PMID = 19212833.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA070892; United States / NCI NIH HHS / CA / CA070892-10; United States / NCI NIH HHS / CA / R01 CA070892-10; United States / NCI NIH HHS / CA / CA70892; United States / NIAMS NIH HHS / AR / R01 AR049277; United States / NIAMS NIH HHS / AR / AR049277-08; United States / NIAMS NIH HHS / AR / R01 AR049277-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / Microfilament Proteins; 0 / PDLIM4 protein, human; 0 / Pdlim4 protein, mouse; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ NIHMS284933; NLM/ PMC3086358
  •  go-up   go-down


92. Cheng J, Bawa T, Lee P, Gong L, Yeh ET: Role of desumoylation in the development of prostate cancer. Neoplasia; 2006 Aug;8(8):667-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of desumoylation in the development of prostate cancer.
  • In this review, we report that SENP1, a member of the SENP family, is overexpressed in human prostate cancer specimens.
  • The induction of SENP1 is observed with the chronic exposure of prostate cancer cells to androgen and/or interleukin (IL) 6.
  • Initial in vivo data from transgenic mice indicate that overexpression of SENP1 in the prostate leads to the development of prostatic intraepithelial neoplasia at an early age.
  • Collectively, these studies indicate that overexpression of SENP1 is associated with prostate cancer development.


93. Crow P, Molckovsky A, Stone N, Uff J, Wilson B, WongKeeSong LM: Assessment of fiberoptic near-infrared raman spectroscopy for diagnosis of bladder and prostate cancer. Urology; 2005 Jun;65(6):1126-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of fiberoptic near-infrared raman spectroscopy for diagnosis of bladder and prostate cancer.
  • OBJECTIVES: To determine whether a fiberoptic Raman system, suitable for in vivo use, is able to differentiate between benign and malignant bladder and prostate pathologic findings in vitro.
  • Laboratory studies have shown that the technique can be used to identify and characterize transitional cell carcinoma and prostate adenocarcinoma in vitro.
  • METHODS: A total of 220 Raman spectra were recorded from 29 snap-frozen bladder samples collected at cystoscopic procedures, and 197 Raman spectra were recorded from 38 snap-frozen prostate samples collected at transurethral resection of the prostate.
  • The spectra were correlated with the histologic features and used to construct separate diagnostic algorithms for the bladder and prostate.
  • RESULTS: The bladder algorithm was able to differentiate benign samples (normal and cystitis) from malignant samples (transitional cell carcinoma), with an overall accuracy of 84%.
  • The prostate algorithm was able to differentiate benign samples (benign prostatic hyperplasia and prostatitis) from malignant samples (prostate cancer), with an overall accuracy of 86%.
  • CONCLUSIONS: The results of this study have demonstrated that the clinical Raman system can provide an accurate and objective method to diagnose prostate and bladder cancer in vitro.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Transitional Cell / diagnosis. Prostatic Neoplasms / diagnosis. Spectroscopy, Near-Infrared. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fiber Optic Technology. Humans. In Vitro Techniques. Male. Sensitivity and Specificity


94. Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R: Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate; 2007 Aug 1;67(11):1182-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
  • In this study, we tested the biological effects of the HDAC inhibitor MS-275 in various pre-clinical prostate cancer models both in'vitro and in vivo.
  • RESULTS: MS-275 significantly upregulated histone H3 acetylation and p21 gene expression in human prostate cancer cell lines.
  • Prostate specific antigen protein levels were increased by MS-275 in LAPC4 cell line.
  • In transgenic adenocarcinoma of mouse prostate (TRAMP) mice, long-term treatment of MS-275 slowed the progression of prostate carcinomas with significant reduction in cell proliferation.
  • CONCLUSIONS: Taken together, these data support the clinical testing of MS-275 for the treatment of prostate cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Benzamides / pharmacology. Enzyme Inhibitors / pharmacology. Histone Deacetylase Inhibitors. Prostatic Neoplasms / pathology. Pyridines / pharmacology
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Adenocarcinoma / prevention & control. Animals. Blotting, Western. Cell Cycle / drug effects. Cell Division / drug effects. Cell Line, Tumor. Humans. Male. Mice. Mice, Nude. Neoplasm Transplantation. Prostate-Specific Antigen / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17520666.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Pyridines; 1ZNY4FKK9H / entinostat; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


95. Fukagai T, Maruyama K, Nagata M, Morita M, Naoe M, Yoshida H: Practice patterns regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care practitioners. Int J Urol; 2007 May;14(5):412-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practice patterns regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care practitioners.
  • OBJECTIVE: Although primary care practitioners (PCP) take an active role in diagnosis of prostate disorders in Western countries, how PCP take part in management of prostate disease still differs worldwide by country.
  • We investigated practice and referral patterns concerning prostate disease among Japanese PCP and compared these with reported patterns in the West.
  • Most items involved prostate cancer screening or management of benign prostatic hyperplasia (BPH).
  • Prostate-specific antigen (PSA) was determined in serum by 89%.
  • Seventy-four percent prescribed medication for benign prostate hypertrophy; among these respondents, 87% reported common use of alpha-blockers.
  • Although 31% of respondents were aware of the International Prostate Symptom Score (IPSS), only 2% used it.
  • CONCLUSIONS: Although Japanese PCP were involved increasingly in diagnosis and management of prostate disease, degree and proficiency of involvement were too limited and less than in Western countries.
  • Continuing medical education appears desirable for PCP in Japan regarding prostate disease.
  • [MeSH-major] Practice Patterns, Physicians'. Primary Health Care. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / therapy. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / therapy


96. Parwani AV, Marlow C, Demarzo AM, Mikolajczyk SD, Rittenhouse HG, Veltri RW, Chan TY: Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer. Am J Surg Pathol; 2006 Oct;30(10):1231-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.
  • Precursors of prostate-specific antigen (proPSA) have been previously shown to be more concentrated in prostate cancer tissue.
  • This study characterizes the immunohistochemical staining (IHS) of proPSA forms in metastatic prostate cancer compared with prostate specific antigen (PSA) and prostatic acid phosphatase (PAP).
  • A tissue microarray, consisting of 74 cases of metastatic prostate carcinoma and control tissues, was used.
  • The monoclonal antibodies were specific for both benign and malignant prostatic glandular tissue.
  • [-5/-7]pPSA (native proPSA) may be a better marker than PSA and PAP in characterizing metastatic prostate adenocarcinoma, with most of the cases showing positivity for the marker.
  • Such enhanced detection is particularly important in poorly differentiated carcinomas involving metastatic sites where prostate carcinoma is a consideration.
  • A panel of markers, including proPSA, should be performed when metastatic prostate carcinoma is in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / chemistry. Immunoenzyme Techniques / methods. Prostate-Specific Antigen / analysis. Prostatic Neoplasms / chemistry. Protein Precursors / analysis. Protein Tyrosine Phosphatases / analysis